CA2178632C - Pharmaceutical compositions containing hiv protease inhibitors - Google Patents

Pharmaceutical compositions containing hiv protease inhibitors Download PDF

Info

Publication number
CA2178632C
CA2178632C CA002178632A CA2178632A CA2178632C CA 2178632 C CA2178632 C CA 2178632C CA 002178632 A CA002178632 A CA 002178632A CA 2178632 A CA2178632 A CA 2178632A CA 2178632 C CA2178632 C CA 2178632C
Authority
CA
Canada
Prior art keywords
weight
solution
total solution
amino
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002178632A
Other languages
French (fr)
Other versions
CA2178632A1 (en
Inventor
Laman A. Al-Razzak
Kennan C. Marsh
Lourdes P. Manning
Dilip Kaul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002540258A priority Critical patent/CA2540258A1/en
Publication of CA2178632A1 publication Critical patent/CA2178632A1/en
Application granted granted Critical
Publication of CA2178632C publication Critical patent/CA2178632C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1): (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol (40) hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof; and (2) ethanol or propylene glycol.

Description

2~! ~~63 2 PHARMACEUTICAL COMPOSITIONS CONTAINII~1G HIV PROTEASE
INHIBITORS
Technical Field A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV
protease (in particular, HIV-1 and HIV-2 protease). Tn particular, the composition comprises the HIV protease inhibitor and one or more pharmaceutically acceptable organic solvents.
Background of the Invention One measure of the potential usefulness of an oral dosage form of a new pharmaceutical agent is the bioavailability observed after oral administration of the dosage form. Various factors can affect the bioavailability of a drug when administered orally. These factors include aqueous solubility, drug absorption throughout the gastrointestinal tract, dosage strength and first pass effect.
Aqueous solubility is one of the most important of these factors. When a drug has poor aqueous solubility, attempts are often made to identify salts or other derivatives of the drug which have improved aqueous sollubility. When a salt or other derivative of the drug is identified which has good aqueous solubility, it is generally accepted that an aqueous solution formulation of this alt or derivative will provide the optimum oral bioavailability. The bioavailability of the aqueous oral solution formulation of a drug is then generally used as the standard or ideal bioavailability against which other oral dosage forms are measured.

WO 95/20384 ~ ~ ~ PCT/US95/(10232 It has recently been determined that HIV protease inhibiting compounds are useful for inhibiting HIV protease vitro and i viv and are useful for inhibiting an HIV (human immunodeficiency virus) infection and are useful for treating AIDS (acquired immunodefficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability.
Examples of HIV protease inhibiting compounds include N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5~-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide and related compounds, disclosed in European Patent Application No. EP541168, published May 12, 1993;
N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide and related compounds, disclosed in U.S. Patent No. 5,196,438, issued March 23, 1993;
[1 S-[1 R*(R*),2S*]}-N~ [3-[[[(1,1-dimethylethyl)ami no]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide and related compounds, disclosed in PCT Patent Application No. W092/08701, published May 29, 1992; and \ O -HO N' _N \ / OH
\ ~ HO OH \
and related compounds, disclosed in PCT Patent Application No. W093/07128, published April 15, 1993.

WO 95/20384 217 8 6 3 2 p~~S9s/00232 It has recently been determined that compounds of the formula I:

w N CH3 R2 OH O
N ~I,~
S ~ NH ~O , NH~ i I N H O ~N
O Ri S,~,/

wherein R1 is lower alkyl and R2 and R3 are phenyl are inhibitors of HIV-1 and HIV-2 protease and are useful for inhibiting HIV protease in ' r and in vivo and are useful to inhibit HIV (human immunodeficiency virus) infections and, thus, are useful for the treatment of AIDS (acquired immunodeficiency syndrome).
In particular, the compound of formula II, has been found to be especially effective as an inhibitor of HIV-1 and HIV-2 protease.

S ., N I Hs O O
~N H
H~O~N
O CH3 Ct The most preferred compound of formula II is (2S.3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane (compound III).
Compound III has an aqueous solubility of approximately 6 micrograms per milliliter at pH >2. This is considered to be extremely poor aqueous solubility and, therefore, compound III in the free base form would be expected to provide very low oral bioavailability. In fact, the free base form of compound III, administered as an unformulated solid in a capsule dosage form, is 4 217 8 b 3 2 PCT~S95/00232 characterized by a bioavailability of less than 2% following a 5 mg/kg oral dose in dogs.
Acid addition salts of compound III (for example. bis-hydrochloride, bis-tosylate, bis-methane sulfonate and the like) have aqueous solubilities of <0.1 milligrams/milliliter. This is only a slight improvement over the solubility of the free base. This low aqueous solubility would not make practical the administration of therapeutic amounts of compound III as an aqueous solution.
Furthermore, in view of this low aqueous solubility, it is not surprising that the bis-tosylate of compound III, administered as an unformulated solid in a capsule dosage form, is characterized by a bioavailability of less than 2%
following a 5 mg/kg oral dose in dogs.
In order to have a suitable oral dosage form of compound III, the oral bioavailability of compound III should be at least 20%. Preferably, the oral bioavailability of compound III from the dosage form should be greater than about 40% and, more preferably, greater than about 50%.
While some drugs would be expected to have good solubility in organic solvents, it would not necessarily follow that oral administration of such an organic solution would give good bioavailability for the drug. It has been found that compound I11 has good solubility in pharmaceutically acceptable organic solvents. In addition, the solubility of compound III in some organic solvents is enhanced in the presence of a pharmaceutically acceptable acid.
Unexpectedly, solutions of compound III in pharmaceutically acceptable organic solvents provide an oral bioavailability of from about 40% to about 100% in dogs.
Disclosure of the Invention In accordance with the present invention, there is a pharmaceutical com-position comprising a solution of an HIV protease inhibiting compound (preferably, a compound of the formula II) in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate s WO 95/20384 21 ~ g ~ 3 2 PCT/US95I00232 and 2-(2-ethoxyethoxy)ethanoi or (c) a mixture thereof and (2) ethanol or propylene glycol.
A preferred composition of the invention comprises a solution of an HIV
protease inhibiting compound (preferably, a compound of the formula II) in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) propylene glycol or polyoxyethyleneglycerol triricinoleate or a mixture thereof and (2) ethanol.
The solution composition of the invention can also comprise other pharmaceutically acceptable organic solvents.
The solution composition of the invention can also comprise from about 0% to about 20% (preferably, from about 0.2% to about 16% and more preferably from about 0.2% to about 6%, by weight of the total solution) of a pharmaceutically acceptable acid or a mixture of pharmaceutically acceptable acids.
The solution composition of the invention can also comprise from about 0% to about 25% (preferably, from about 0% to about 19%, by weight of the total solution) of water.
The solution composition of the invention can also comprise one or more pharmaceutically acceptable oils.
The solution of the invention can also comprise pharmaceutically acceptable sweetening agents and/or pharmaceutically acceptable flavoring agents (for example, sucrose, aspartame, sorbitol, saccharin sodium and the like and/or cherry flavor, artificial banana flavor, caramel, chocolate mint flavor, grape flavor, wild cherry flavor, raspberry flavor, strawberry flavor, citrus flavor, orange flavor, pineapple flavor, citrus lime flavor, citrus cream flavor, cherry vanilla flavor, creme de menthe flavor and the like).
In addition, the solution composition of the invention can comprise one or more pharmaceutically acceptable surfactants.
In addition, the solution composition of the invention can comprise antioxidants (for example, ascorbic acid, BHA (butylated hydroxyanisole), BHT
(butylated hydroxytoluene), vitamin E, vitamin E PEG 1000 succinate and the like) for chemical stability.
The compositions of this invention provide improved oral bioavailability for compound II when compared to non-formulated compound II (base) or non-WO 95/20384 217 8 b 3 2 pCT~S95100232 formulated compound II (acid addition salt), or even when compared to a mixed aqueous/organic solution (50% water, 20% ethanol, 30% propylene glycol) of compound II (methansulfonate acid addition salt).
The term "pharmaceutically acceptable organic solvent" as used herein refers to propylene glycol; polypropylene glycol; polyethylene glycol (for example, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 900, polyethylene glycol 540 (all available from Union Carbide) and the like); pharmaceutically acceptable alcohols (for example, ethanol or 2-(2-ethoxyethoxy)ethanol (Transcutol~ , Gattefosse, Westwood, NJ
07675) and the like); polyoxyethylene castor oil derivatives (for example, polyoxyethyleneglycerol triricinoleate or polyoxyl 35 castor oil (Cremophor~EL, BASF Corp.), polyoxyethyleneglycerol oxystearate (Cremophor~RH 40 (polyethyleneglycol 40 hydrogenated castor oil) or Cremophor~RH 60 (polyethyleneglycol 60 hydrogenated castor oil), BASF Corp.) and the like);
fractionated coconut oil (for example, mixed triglycerides with caprylic acid and capric acid (Miglyol~812, available from Huls AG, Witten, Germany) and the like); Tween~ 80; isopropyl palmitate; isopropyl myristate; pharmaceutically acceptable silicon fluids; and the like.
The term "pharmaceutically acceptable acid" as used herein refers to (i) an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid and the like, (ii) an organic mono-, di- or tri-carboxylic acid (for example, formic acid. acetic acid, adipic acid, alginic acid, citric acid, ascorbic acid, aspartic acid, benzoic acid, butyric acid, camphoric acid, gluconic acid, glucuronic acid, galactaronic acid, glutamic acid, heptanoic acid, hexanoic acid, fumaric acid, lactic acid, lactobionic acid, malonic acid, malefic acid, nicotinic acid, oxalic acid, pamoic acid, pectinic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, succinic acid, tartaric acid, undecanoic acid and the like) or (iii) a sulfonic acid (for example, benzenesulfonic acid, sodium bisulfate, sulfuric acid, camphorsulfonic acid, dodecylsulfonic acid, ethanesulfonic acid, methanesulfonic acid, isethionic acid, naphthalenesulfonic acid, p-toluenesulfonic acid and the like).
The term " pharmaceutically acceptable oil" as used herein refers to mineral oil or a vegetable oil (for example, safflower oil, peanut oil, olive oil, fractionated coconut oil (for example, mixed triglycerides with caprylic acid and ,._. WO 95/20384 u. .. .,.._...~ ~ ~ PCTIUS95/00232 _7-capric acid (Miglyol~812, available from Huls AG, Witten, Germany) and the like).
The term "pharmaceutically acceptable surfactant" as used herein refers to a pharmaceutically acceptable non-ionic surfactant (for example, polyethylenepolypropylene glycol, such as Poloxamer~'68 (BASF Wyandotte Corp.) or a mono fatty acid ester of polyoxyethylene (20) sorbitan (for example, polyoxyethylene (20) sorbitan monooleate (Tween~ 80), polyoxyethylene (20) sorbitan monostearate (Tween~ 60), polyoxyethylene (20) sorbitan monopalmitate (Tween~ 40), polyoxyethylene (20) sorbitan monolaurate (Tween~ 20) and the like) and the like) or a pharmaceutically acceptable anionic surtactant (for example, sodium lauryl sulfate and the like).
A preferred composition of the invention comprises an HIV protease inhibiting compound (preferably, a compound of the formula II) in the amount of from about 1 % to about 15% by weight of the total solution (more preferably, from about 2.5% to about 10% by weight of the total solution) in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) (a) a solvent selected from propylene glycol and polyethylene glycol in the amount of from about 10% to about 50% by weight of the total solution or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanoi in the amount of from about 5% to about 35% by weight of the total solution or (c) a mixture thereof and (2) ethanol or propylene glycol in the amount of from about 5% to about 45% by weight of the total solution (more preferably, from about 20% to about 35% by weight of the total solution).
Preferably, in the composition of the invention, the mixture of pharmaceutically acceptable organic solvents (including ethanol) comprises from about 50% to about 95% by weight of the total solution. More preferably, the mixture of pharmaceutically acceptable organic solvents comprises from about 70% to about 95% by weight of the total solution.
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 42% by weight of the total solution), ethanol (about 32% by weight of the total WO 95/20384 ~ 3 ~ PCT/US95100232 _g_ solution) and water (from about 16% to about 17% by weight of the total solution).
In the composition of the invention, a preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 32% by weight of the total solution), ethanol (about 37% by weight of the total solution) and water (about 15% by weight of the total solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (from about 44% to about 45% by weight of the total solution), polyoxyethyleneglycerol triricinoleate (about 20% by weight of the total solution) and ethanol (from about 24% to about 25% by weight of the total solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (from about 39% to about 40% by weight of the total solution), polyoxyethyleneglycerol triricinoleate (about 20% by weight of the total solution) and ethanol (about 24% by weight of the total solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 43% by weight of the total solution), ethanol (about 33% by weight of the total solution) and water (about 17% by weight of the tptal solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 36% by weight of the total solution), ethanol (about 36% by weight of the total solution) and water (about 19% by weight of the total solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 35% by weight of the total solution), ethanol (about 35% by weight of the total solution) and water (about 18% by weight of the total solution).

WO 95/20384 ~ ~~ PCT/US95/00232 _g_ In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 31 % by weight of the total solution), polyoxyethyleneglycerol triricinoleate (about 10% by weight of the total solution), ethanol (about 32% by weight of the total solution)and water (about 14% by weight of the total solution).
In the composition of the invention, another preferred mixture of pharmaceutically acceptable solvents is a mixture of propylene glycol (about 46% by weight of the total solution), ethanol (about 21 % by weight of the total solution) and poiyoxyethyleneglycerol triricinoleate (about 24% by weight of the total solution).
A preferred pharmaceutically acceptable acid is citric acid.
A most preferred composition of the invention comprises a solution of a compound of the formula III in the amount of from about 1 % to about 15% by weight of the total solution (more preferably, from about 2.5% to about 12% by weight of the total solution) in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) propylene glycol or polyoxyethyleneglycerol triricinoleate or a mixture thereof and (2) ethanol.
In the most preferred composition of the invention, the preferred pharmaceutically acceptable solvents and acids are as described above for the preferred composition of the invention.
An even more preferred composition of the invention comprises a solution of a compound of the formula III in the amount of from about 5% to about 8% by weight of the total solution in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) propylene glycol in the amount of from about 34% to about 36% by weight of the total solution, (2) ethanol in the amount of from about 34% to about 36% by weight of the total solution and (3) water in the amount of from about 18% to about 19% by weight of the total solution. The even more preferred composition also comprises citric acid in the amount of from about 0.3% to about 0.4% by weight of the total solution.

WO 95/20384 ~ ~ PCT/US95100232 Another even more preferred composition of the invention comprises a solution of a compound of the formula III in the amount of from about 7% to about 8% by weight of the total solution in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) propylene glycol in the amount of from about 45% to about 46% by weight of the total solution, (2) ethanol in the amount of about 21 % by weight of the total solution and (3) polyoxyethyleneglycerol triricinoleate in the amount of from about 24% to about 25% by weight of the total solution. The even more preferred composition also comprises citric acid in the amount of about 0.5% by weight of the total solution.
A most highly preferred composition of the invention comprises a solution of a compound of the formula III in the amount of from about 7% to about 8% by weight of the total solution in a pharmaceutically acceptable organic solvent comprising a mixture of (1 ) propylene glycol in the amount of from about 31 % to about 32% by weight of the total solution, (2) ethanol in the amount of about 32% by weight of the total solution, (3) polyoxyethyleneglycerol triricinoleate in the amount of from about 10% to about 11 % by weight of the total solution and (4) water in the amount of from about 14% to about 15% by weight of the total solution. The even more preferred composition also comprises citric acid in the amount of from about 0.2% to about 0.3% by weight of the total solution.
The compounds of formula I and II contain two or more asymmetric carbon atoms and thus can exist as pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates. The present invention is intended to include within its scope all of the isomeric forms. The terms "R" and "S" configuration as used herein are as defined by IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-30.
The preferred isomer of the compound of formula II is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)-valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane (compound III).

,,-.. W0 95/203$4 ~ ~ PCTIUS95/00232 The term "lower alkyl" as used herein refers to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
In general, the compositions of this invention can be prepared in the following manner. The ethanol and the pharmaceutically acceptable acid (if present) and the water (if present) and sweetener (if present) are mixed. To this solution is added the propylene glycol or polyethylene glycol and/or polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate or 2-(2-ethoxyethoxy)ethanol until the resulting solution is clear. Compound III
(along with any other solvents. oils or other additives) are added to the solution and mixed until the solution is clear. The resulting solution is brought to the desired final volume with the addition of propylene glycol or polyethylene glycol and/or polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate or 2-(2-ethoxyethoxy)ethanol.
Alternatively, the ethanol and pharmaceutically acceptable acid (if present) are mixed, followed by addition of compound III. To this mixture is added the propylene glycol or polyethylene glycol and/or polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate or 2-{2-ethoxyethoxy)ethanol until the resulting solution is clear. Then the water (if present) and sweetener (if present), along with any other solvents, oils or other additives, are added with mixing until the solution is clear. The resulting solution is brought to the desired final volume with the addition of, propylene glycol or polyethylene glycol and/or polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate or 2-(2-ethoxyethoxy)ethanol.
The following examples will serve to further illustrate the invention. In particular, Examples 5-19 relate specifically to this invention.

xaml~le 1 i(non-formulated ca sIZ ulel An amount of compound 111 (free base) equivalent to a 5 mg/kg dose was placed in hard gelatin capsules (gray, size 0). These capsules were administered to fasted dogs with 10 ml of water.
Exam I~ a 2 ~(Ca~ s~ ule) An amount of compound III (free base) equivalent to a 5 mg/kg dose was placed in hard gelatin capsules (gray, size 0). These capsules were administered to non-fasted dogs with ten milliliter of water.
An amount of the bis-tosylate salt of compound III equivalent to a mg/kg dose of compound III (base equivalent) was filled into hard gelatin capsules (gray, size 0). These capsules were administered to nonfasted dogs with ten milliliter of water.
Examlhe 44 lSolutionl A 5 mg (free base equivalent)/ml solution of the base compound III in 20% ethanol: 30% propylene glycol: dextrose containing 2- molar equivalents of methane sulfonic acid.
Component % BK Weiaht Compound III (free base) 0.5 Propylene glycol (Aldrich, reagent) 31.9 Ethanol (USP, 200 proof) 16.2 methanesulfonic acid (Aldrich reagent) 0.14 Dextrose 3.6 Water for injection (USP) 47.6 A 50 mg/ml solution of the base compound III.
~o~r ~oonent % B~ Weiaht Compound III (free base) 5.1 Propylene glycol (USP) 42.22 Ethanol (USP, 200 proof, dehydrated)32.21 Citric acid (USP, anhydrous, powder)3.93 Water for injection (USP) 16.54 ......, WO 95/20384 PCT/US95/00232 Citric acid (77.0 g) was mixed with water (300 mL) and stirred until the solution was clear. Water was added to bring the volume of solution to 400 mL.
Propylene glycol (300 g) and ethanol (800 g) were mixed in a stainless steel beaker until the solution was clear. To the propylene glycol/ethanol solution was added compound III (100.4 g) with stirring and mixing was continued until the solution was clear. To this solution was added the citric acid solution until the final volume was 2000 mL.
If a flavoring agent is to be included, it would be added to the solution of compound III prior to addition of the citric acid solution.
Exam of A 25 mg/ml solution of the base compound III.
Comioor nent % B~ eight Compound III (free base) 2.6 Propylene glycol (USP) 43.4 Ethanol (USP, 200 proof, dehydrated)33.04 Citric acid (USP, anhydrous, powder)4.0 Water for injection (USP) 16.95 Examnl, a 7 A 50 mg/ml solution of the base compound III.
Co,p~a o~ nent % By Weight Compound III (free base) 5.37 Propylene glycol (USP) 28.85 Ethanol (USP, 200 proof, dehydrated)43.35 Citric acid (USP, anhydrous, powder)4.3 Water for injection (USP) 18.14 Exarndle 8 A 50 mg/ml solution of the base compound III.
Component % By, Weight Compound III (free base) 5.3 Propylene glycol (USP) 31 Ethanol (USP, 200 proof, dehydrated)42.1 Citric acid (USP, anhydrous, powder)3.8 Water for injection (USP) 16.05 Aspartame 1.60 Wild cherry flavor 0.14 Exam i A 50 mg/ml solution of the base compound III.
Coml oa nent % By Weight Compound III (free base) 5.39 Cremophor~ EL (polyoxyl 35 castor oil, NF) 32.18 Ethanol (USP, 200 proof, dehydrated) 32.3 Miglyol~ 812 30.13 Exam~ile 10 A 50 mg/ml solution of the base compound III.
Component % B,~r Weight Compound III (free base) 5.01 Propylene glycol (USP) 44.6 Ethanol (USP. 200 proof, dehydrated)24.53 ~

Citric acid (USP, anhydrous, powder)5.76 .

Cremophor~ EL (polyoxyl 35 castor 20.1 oil, NF) WO 95!20384 PCT/US95/00232 ~~~8~3Z

F~.aI~LI~.. L~
A 50 mgiml solution of the base compound !i1.
~y Weight Compound III (free base) 5.04 Propylene glycol (USP) 44.39 Ethanol (USP, 200 proof, dehydrated) 24.42 Citric acid (USP, anhydrous, powder) 5.82 Cremophor~ EL (polyoxyl 35 castor 20.33 oil, NF) Citric acid (153.6 g) and ethanol (800 mL) were mixed until the solution was clear. To this solution was added with mixing polyoxyl 35 castor oil (400 g) and enough propylene glycol until the solution was clear. Compound III (100 g) was added with mixing until the solution was clear. Propylene glycol was added to bring the final volume of the solution to 2000 mL.
Alternatively, citric acid (153.6 g) and ethanol (800 mL) were mixed until the solution was clear. Compound III (100 g) was added with mixing until the solution was clear. To this solution was added with mixing polyoxyl 35 castor oil (400 g) and enough propylene glycol until the solution was clear.
Propylene glycol was added to bring the final volume of the solution to 2000 mL.
A 50 mg/ml solution of the base compound III.
~~noonent % By W~_h_t Compound III (free base) 5.11 Propylene glycol (USP) 24.05 Ethanol (USP, 200 proof, dehydrated)20.29 Cremophor~ EL (polyoxyl 35 castor 35.59 oil, NF) Miglyol~ 812 5.0 Tween~ 80 9.97 ~ 1 l 8 b 3 2 pCTNS95100232 Exam!. In a 13 A 100 mg/ml solution of the base compound III.
J~ Iffy Weight Compound III (free base) 10.05 Propylene glycol (USP) 39.64 Ethanol (USP, 200 proof, dehydrated) 24.3 Cremophor~ EL (polyoxyl 35 castor oil, NF) 20.23 Citric acid (USP, anhydrous, powder) 5.76 Fx.~mQl~ a ~ 4 A 100 mg/ml solution of the base compound III.
Component % Bv Weight Compound III (free base) 499 Propylene glycol (USP) 43.52 Ethanol (USP, 200 proof, dehydrated)24.2 Cremophor~ EL (polyoxyl 35 castor 19.96 oil, NF) Citric acid (USP, anhydrous, powder)5.76 .

Banana flavor 0.5 Strawberry flavor 0.59 Sodium saccharin 0.5 Exam I~e 15 A 130 mg/ml solution of the base compound III.
Com op vent % By Weight Compound III (free base) 12.0 Propylene glycol (USP) 32.4 Ethanol (USP, 200 proof, dehydrated) 37.0 Citric acid (USP, anhydrous, powder) 3.6 Water for injection (USP) 15.0 2 ~ 18b32 ~~amnle 16 A 50 mg/ml solution of the base compound III.
Coma onent % By Wei~L

Compound III (free base) 5.125 Propylene glycol (USP) 35.8 Ethanol (USP, 200 proof, dehydrated)35.75 Citric acid (USP, anhydrous, powder)0.362 Water for injection (USP) 18.86 Sodium Saccharin (USP, powder, dihydrate)1.02 Wild cherry flavor, artificial 3.0 Flavor enhancer (Prosweet~ Liquid 0.08 "K") (Prosweet~ Liquid "K" is available from Virginia Dare, 882 Third Ave., Brooklyn, NY) Dye, Red D&C No. 33 0.01 ~Eamh,~e 17 An 80 mg/ml solution of the base compound I11.
C~ % By Weioht Compound III (free base) 7.96 Propylene glycol (USP) 34.72 Ethanol (USP, 200 proof, dehydrated)34.7 Citric acid (USP, anhydrous, powder)0.35 Water for injection (USP) 18.3 Sodium Saccharin (USP, powder, dihydrate)0.99 Wild cherry flavor, artificial 2.9 Flavor enhancer (Prosweet~ Liquid 0.08 "K") Dye, Red D&C No. 33 0.01 WO 95/20384 217 a 6 3 2 pCT~S95/00232 _.

Exan~,~le 1$
An 80 mg/ml solution of the base compound II1.
By Weiaht Compound III (free base) 7.88 Propylene glycol (USP) 31.31 Ethanol (USP, 200 proof, dehydrated) 32.0 Citric acid (USP, anhydrous, powder) 0.27 Water for injection (USP) 14.18 Cremophor~ EL 10.4 Sodium Saccharin (USP, powder, dihydrate)0.98 Wild cherry flavor, artificial 2.875 Flavor enhancer (Prosweet~ Liquid 0.08 "K") Dye, Red D&C No. 33 0.01 The water (14.4 mL) and ethanol (41.2 mL) were mixed and the citric acid (276 mg) was added with stirring. The sodium saccharin (1.0 g), flavor enhancer (0.1 mL), propylene glycol (30.7 mL), compound III (8.0 g), red dye (10.0 mg), and cherry flavor (3.7 mL) were added sequentially with stirring.
The resulting solution was brought to a final volume of 100 mL by addition of the Cremophor~ EL. The final solution was stored at 2-8°C until it was filled into 15 mL vials.
ExamQle 19 An 80 mg/ml solution of the base compound III.
By Weiaht Compound III (free base) 7.57 Propylene glycol (USP) 45.7 Ethanol (USP, 200 proof, dehydrated)21.0 Citric acid (USP, anhydrous, powder)0.51 Cremophor~ EL 24.29 Sodium Saccharin (USP, powder, dihydrate)0.47 Flavor enhancer (Prosweet~ Liquid 0.148 "K") Flavor, chocolate mint 0.37 ._. WO 95/20384 ~ ~ ~ ~ ~ PCTIUS95/00232 _19_ The ethanol (28.4 mL) were mixed and the citric acid (545 mg) was added with stirring. Enough of the propylene glycol was added with stirring to make the resulting solution clear. The sodium saccharin (500 mg), flavor enhancer (0.2 mL), compound 111 (8.0 g), Cremophor~ EL (24.5 mL), and chocolate mint flavor (0.5 mL) were added sequentially with stirring. The resulting solution was brought to a final volume of 100 mL by addition of propylene glycol. The final solution was stored at 2-8°C until it was filled into 15 mL vials.
The remaining examples provide the preparation of compound III.
F.~~~I~Ihe 2~
(2S.3S.5S~-5 (,~~;jN~"jf~l-MevkhY,l-~j2-iso~,~yJ-4-tniazolyl)methyl,aa~-ulrlStlgalbonyj)valinyl)aminr,~-2-(,N-A. N-.LtB~~n~~:~Yl~x~,~~ r,onYl)-L-~h~o.~~ final.
A solution of 24.5 ml of anhydrous dimethyl sulfoxide in 870 ml of anhydrous dichloromethane was cooled under N2 atmosphere to -60~C and treated over a period of 15 min with 131 ml of a 2 M solution of oxalyl chloride in dichloromethane in order that the internal temperature remained below -50~C.
After addition, the solution was stirred at -60~C for 15 min and treated over a period of 20 min with a solution of 50 g (0.175 mol) of N-(((benzyl)oxy)-carbonyl)-L-phenylalaninol in 200 ml of dichloromethane. The resulting solution was stirred at -60°C for 1 h, then treated over a period of 15 min with 97 ml of triethylamine in order that the internal temperature remained below -50~C. After addition the solution was stirred at -60~C for 15 min, then, with the cooling bath in place, was treated rapidly (over a period of 1 min) with a solution of 163 g of citric acid in 550 ml of water. The resulting slurry was stirred vigorously for 10 min, allowed to warm, diluted to 1 liter with water, and separated. The organic layer was washed with 700 ml of water followed by a WO 95120384 217 8 b 3 2 PCT/US95100232 mixture of 550 ml of water and 150 ml of saturated aqueous NaHC03, dried over MgS04, and concentrated in vacuo at 20~C to give the crude desired compound as a light yellow solid.
B ,~2S 3R 4R 5S1-2 5-Bis-(N_(,~(benzyl)oxv)carbonyllaminol-3.4-dihvdroxv-1.6 diohen~hexane and (2S 3S 4S 5SL2 5-Bis-(N-(((benzvlloxv)carbonvllaminol 3 4-dihvdrox~l .6-diahenvlhexane.
A suspension of 78.5 g of VC13~(tetrahydrofuran)3 and 16 g of zinc dust in 400 ml of dry dichloromethane was stirred under N2 atmosphere for 1 h at 25~C. A solution of 0.175 mol of N-(((benzyl)oxy)carbonyl)-L-phenylalaninal in 200 ml of dichloromethane was then added in one portion, and the resulting mixture was stirred at ambient temperature under N2 atmosphere for 16 h. The resulting mixture was added to 500 ml of 1 M aqueous HCI, diluted with 500 ml of hot chloroform, and shaked vigorously for 2 min. The layers were separated, and the organic layer was washed with 1 M aqueous HCI and separated.
Filtration of the organic phase provided the crude desired product as a solid residue. The residue was slurried in 1.25 liters of acetone, treated with 5 ml of concentrated H2S04, and stirred for 16 h at ambient temperature. The resulting mixture was filtered, and the residue (residue A) was washed with 50 ml of acetone. The combined filtrate was concentrated to a volume of 250 ml, diluted with 1000 ml of dichloromethane, washed three times with water and once with saturated brine, dried over MgS04, and concentrated to give a viscous oil. The oil was taken up in 1000 ml of 1 M HCI in methanol (prepared from 71 ml of acetyl chloride and 1000 ml of methanol) and stirred at ambient temperature for 2 h. The resulting precipitate was filtered, washed with methanol, and air-dried on the filter to provide 26.7 g of the desired compound as a white solid. The filtrate was concentrated and filtered to give a second crop (8.3 g) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. ~ H NMR (d6-DMSO) 8 2.59 (dd, J = 13, 5 Hz, 2 H), 2.74 (dd, J = 13, 9 Hz, 2 H), 3.26 (br, 2 H), 4.19 (m, 2 H), 4.54 (m, 2 H), 4.92 (m, 4 H), 6.82 (d, J = 9 Hz, 2 H), 7.0-7.35 (m, 20 H). Mass spectrum: (M + H)+
_ 569.

WO 95/20384 217 8 6 3 2 PCT~S95/00232 Residue A (above, 2.65 g) was suspended in 75 ml of tetrahydrofuran (THF) and 75 ml of 1 M aqueous HCI and heated at reflux for 24 h. After concentration of the resulting solution in vacuo, the residue was taken up in 10% methanol in chloroform, washed two times with water, dried over Na2S04, and concentrated in vacuo to provide (2S,3S,4S,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane as a white solid. ~ H NMR (ds-DMSO) 8 2.64 (m, 2 H), 3.04 (m, 2 H), 3.49 (m, 2 H), 3.78 (m, 2 H), 4.70 (d, J = 7 Hz, 2 H), 4.93 (AA', 4 H), 7.1-7.4 (m, 20 H). Mass spectrum:
(M + H)+ = 569.
x r n I mi brgmo,~l.~6-dia~henvl, hex,~,0e.
A suspension of 25 g (44 mmol) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane in 500 ml of 2:1 dichloromethane/hexane was treated with 23 g of a-acetoxyisobutyryl bromide. The resulting mixture was stirred at ambient temperature until the reaction clarified, washed with two 200 ml portions of saturated aqueous NaHC03, dried over MgS04, and concentrated in vacuo to give 30.8 g of the crude desired compound. A portion was purified by silica gel chromatography using 9:1 dichlorornethane:ethyl acetate to provide the pure desired compound as a white solid. 1 H NMR (CDC13) 8 2.21 (s, 3 H), 2.62 (dd, J
= 13, 11 Hz. 1 H), 2.75 (d, J = 7 Hz, 2 H), 2.95 (br d, J = 15 Hz, 1 H), 4.03 (br t, J
= 10 Hz, 1 h), 4.40 (br d, J = 10 Hz, 1 H); 4.6-5.0 (m, 6 H), 5.12 (br d, J =
13 Hz, 1 H), 5.33 (br d, J = 11 Hz, 1 H), 7.0-7.4 (m, 10 H). Mass spectrum: (M + NH4)+
_ 690, 692.
D. (2S.3R.4R.5S)-2.5-Bis-fN-(((benzvl)oxv)carbonvllamino)-3.4-epoxy-1.6-iohenylhexane.
A solution of 35.56 g (52.8 mmol) of (2S,3R,4S,5S)-3-acetoxy-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3-bromo-1,6-diphenylhexane in 375 ml of dioxane was treated with 255 ml of 1 N aqueous sodium hydroxide and stirred at ambient temperature for 16 h, during which the desired compound precipitated. The resulting mixture was filtered, and the residue was washed WO 95120384 ~ ~ l 8 6 3 2 PCT/US95/00232 with water and dried to provide 22.23 g (76%) of the desired compound as a white solid. 1 H NMR (CDC13) 8 2.7-2.9 (m, 6 H), 3.9-4.0 (m, 2 H), 4.6-4.7 (m, H), 5.03 (m, 4 H), 7.1-7.4 (m, 10 H).
E L2S 3S 5SL2 5-Bis- N-(((benzy~oxv carbonvllamino)-1.6-diohenvl-3 ~droxyhexane.
A mixture of 39.2 g (71.2 mmol) of (2S,3R,4R,5S)-2,5-bis-(N-(((benzyl)oxy)carbonyl)amino)-3,4-epoxy-1,6-diphenylhexane in 600 ml of THF
was treated under N2 atmosphere with 13 g (0.36 mol) of sodium borohydride.
The resulting mixture was treated dropwise with 27.7 ml (0.36 mol) of trifluoroacetic acid. After being stirred for 3.5 h at ambient temperature, the resulting mixture was quenched with 1 N aqueous HCI, diluted with water, and stirred for 16 h. The resulting mixture was filtered. washed with water, and dried to provide 22.85 g (58%) of the desired compound as a white solid.
~2S 3S 5S~2 5-Diamino-1.6-di~~henyl-3-hvdroxyhexane.
A suspension of 32 g of the crude resultant compound of Example 20E
and 55.5 g (176 mmol) of barium hydroxide octahydrate in 400 ml of 1,4-dioxane and 400 ml of water was heated at reflux for 4 h. The resulting mixture was filtered, and the residue was rinsed with dioxane. The combined filtrates were concentrated to a volume of approximately 200 ml and extracted with four 400 ml portions of chloroform. The combined organic layers were dried over Na2S04, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography using first 2% isopropylamine in chloroform and then 2%
isopropylamine/2% methanol in chloroform to provide 10.1 g (81 °,%) of the pure desired compound as a white solid. 1 H NMR (CDC13) 8 1.54 (dt, J = 14, 10 Hz, 1 H), 1.67 (dt, J = 14, 3 Hz, 1 H), 2.50 (dd, J = 13, 8 Hz, 1 H), 2.58 (dd, J
= 13, 8 Hz, 1 H), 2.8 (m, 2 H), 2.91 (dd, J = 13, 5 Hz, 1 H), 3.10 (m, 1 H), 3.72 (ddd, J =
11, 3, 2 Hz, 1 H), 7.1-7.4 (m, 10 H). Mass spectrum: (M + H)+ = 285.

,..., WO 95/20384 ~ ~ ~ PCT/iJS95/00232 '_Sl-6-(1-Amino-2-nhenvlethvll-4-benzvl-2-ohenvl:~-aza-2-bora-1-A solution of 11.28 g (40 mmoi) of (2S,3S,5S)-2,5-diamino-1,6-diphenyl-3-hydroxyhexane and 4.88 g (40 mmol) of phenylboric acid in 1 liter of toluene was heated at reflux and the water azeotropically removed with the aid of a Dean Stark trap until the distillate was clear. The solvent was then removed in vacuo to provide the crude desired compound which was used immediately without further purification.
H. Thioformamide.
To a cooled (OTC) 2 L three neck round bottom flask equipped with an overhead stirrer charged with a solution of formamide (30.5 mL, 0.76 mol) in 1 L
of diethyl ether was added 89 g (0.19 mol) of phosphorous pentasulfide in small portions. The reaction mixture was allowed to warm to ambient temperature, stirred for 2 h, filtered, and concentrated in vacuo to afford thioformamide as a yellow offensive smelling oil which was used without purification.
I- Ethyl 2-C,~ Ig~ro-2-f2rmvlacetate.
To a three neck 2 L round bottom flask charged with potassium t-butoxide (0.5 mol, 500 mL of a 1 M solution in THF) and 500 mL of dry THF
cooled to O~C was added dropwise from an addition funnel a solution of ethyl chloroacetate (0.5 mol, 53.5 mL) and ethyl formate ( 0.5 mol, 40.4 mL), in 200 mL of THF over 3 hours. After completion of addition, the reaction mixture was stirred for 1 hour and allowed to stand overnight. The resulting solid was diluted with diethyl ether and cooled in an ice bath. Then, the pH was lowered to approximately 3 using 6N HCI. The organic phase was separated, and the aqueous layer was washed 3 times with diethyl ether. The combined ethereal portions were dried over NaS04, and concentrated in vacuo. The crude desired compound was stored at -30~C and used without further purification.
J. Ethvl Thia,?ole-5-carbox~~te.
To a round bottom flask was added 250 mL of dry acetone, 7.5 g (0.123 mol) of thioformamide, and 18.54 g (0.123 mol) of ethyl 2-chloro-2-WO 95!20384 3 ~ PCT/US95100232 formylacetate. The reaction was heated at reflux for 2 hours. The solvent was removed in vacuo, and the residue was purified by chromatography (Si02, 6 cm o.d. column, 100% CHC13, Rf = 0.25) to provide 11.6 g (60%) of the desired compound as a light yellow oil. NMR (CDC13) 8 1.39 (t, J = 7 Hz, 3 H), 4.38 (q, J
= 7 Hz, 2 H), 8.50 (s, 1 H), 8.95 (s, 1 H).
K. 5- Hvdroxymethyllthiazole.
To a precooled (ice bath) three neck 500 mL flask containing lithium aluminum hydride (76 mmol) in 250 mL of THF was added ethyl thiazole-5-carboxylate (11.82 g, 75.68 mmol) in 100 mL of THF dropwise over 1.5 hours to avoid excess foaming. The reaction was stirred for an additional hour, and treated cautiously with 2.9 mL of water, 2.9 mL of 15% NaOH, and 8.7 mL of water. The solid salts were filtered. and the filtrate set aside. The crude salts were heated at reflux in 100 mL of ethyl acetate for 30 min. The resulting mixture was filtered, and the two filtrates were combined, dried over Na2S04, and concentrated in vacuo. The product was purified by silica gel chromatography eluting sequentially with 0% - 2% - 4% methanol in chloroform, to provide the desired compound, Rf = 0.3 (4% methanol in chloroform), which solidified upon standing in 75% yield. NMR (CDC13) 8 4.92 (s, 2 H), 7.78 (s, 1 H), 8.77 (s, 1 H). Mass spectrum: (M + H)+ = 116.
X15-Thiazolyl_ methyl-(4-nitro~~~henyllcarbonate.
A solution of 3.11 g (27 mmol) of 5-(hydroxymethyl)thiazole and excess N-methyl morpholine in 100 ml of methylene chloride was cooled to O~C and treated with 8.2 g (41 mmol) of 4-nitrophenyl chloroformate. After being stirred for 1 h, the reaction mixture was diluted with CHCIg, washed successively with 1 N HCI, saturated aqueous NaHCO3, and saturated brine, dried over NaS04, and concentrated in vacuo. The residue was purified by silica gel chromatography (Si02, 1-2% MeOH/CHCl3, Rf=0.5 in 4% MeOH/CHC13) to yield 5.9 g (78%) of the desired compound as a yellow solid. NMR (CDC13) 8 5.53 (s, 2 H), 7.39 (dt, J = 9, 3 Hz, 2 H), 8.01 (s, 1 H), 8.29 (dt, J = 9, 3 Hz, 2 H), 8.90 (s, 1 H). Mass spectrum: (M + H)+ = 281.

WO 95/20384 ~ PCT/US95100232 M ~2S 3S 5S1-5-Amino-2-(N-(~5-thiazolvl)metf~oxv~bonvllamingl-1 6 ~iinhenvl-3-hvdroxyhe~,~ne and (2,~ ~~ 5 ~,l-2-Amino-5-(y(5-thiazoly,~,=
methoxycarbonyllaminoLl ,~,- ioh~,~,vl-3-hydroxyhexan_e.
A solution of 500 mg (1.76 mmol) of (2S,3S,5S)-2,5-diamino-1,6-diphenyl-3-hydroxyhexane and 480 mg (1.71 mmol) of ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate in 20 ml of THF was stirred at ambient temperature for 4 h. After removal of the solvent in vacuo, the residue was purified by silica gel chromatography using first 2% then 5% methanol in chloroform to provide a mixture of the two desired compounds. Silica gel chromatography of the mixture using a gradient of 0 - 1 - 2% methanol in 93:2 isopropylamine:
chloroform provided 110 mg (16%) of (2S.3S,5S)-5-amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-Biphenyl-3-hydroxyhexane (Rf 0.48, 96:2:2 chloroform:methanol:isopropylamine) and 185 mg (28%) of (2S,3S,5S)-2-amino-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-Biphenyl-3-hydroxyhexane (Rf 0.44, 96:2:2 chloroform:methanol:isopropylamine).
(2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane: NMR (CDC13) 81.3-1.6 (m, 2 H), 2.40 (dB, J = 14, 8 Hz, 1 H), 2.78 (dB, J = 5 Hz, 1 H), 2.88 (d, J = 7 Hz, 2 H), 3.01 (m, 1 H), 3.72 (br q, 1 H), 3.81 (br d, J = 10 Hz, 1 H}, 5.28 (s, 2 H), 5.34 (br d, J = 9 Hz, 1 H), 7.07 (br d, J =
7 Hz, 2 H), 7.15 - 7.35 (m, 8 H), 7.87 (s, 1 H), 8.80 (s, 1 H). Mass spectrum:
(M
+ H)+ = 426.
(2S,3S,5S)-2-Amino-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane: NMR (CDC13) 8 1.55 (Bt, J = 14, 8 Hz, 1 H), 1.74 (m, 1 H), 2.44 (dB, J = 15, 1 Hz, 1 H), 2.75 - 3.0 (m, 4 H), 3.44 (m, 1 H), 4.00 (br t, 1 H), 5.28 (m, 3 H), 7.1 - 7.4 (m, 10 H), 7.86 (s, 1 H), 8.80 (s, 1 H). Mass spectrum: (M
+ H)+ = 426.
N. (2S.3S.5S}-5-Amino-2-(~(5-thia,~_olyl)methoxYcarbonyl,~amino -1 6 djphenvl-3-hydroxyhexane.
A solution of 40 mmol of crude (4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane in 700 ml of anhydrous THF

WO 95120384 217 8 6 3 2 pCT~S95/00232 was cooled to -40~C and treated dropwise over a period of 1 h with a solution of 7.83 g (27.9 mmol) of ((5-thiazolyl)methyl)-(4-nitrophenyl)carbonate in 300 ml of dry THF. The resulting solution was allowed to warm to O~C for 3 h, then to ambient temperature for 16 h. The solvent was removed in vacuo, and the residue was taken up in 700 ml of ethyl acetate, washed with three 150 ml portions of 1 N aqueous NaOH and one 150 ml portion of brine. The organic phase was dried over Na2S04 and concentrated in vacuo. Purification of the residue by silica gel chromatography using methanol/chloroform mixtures provided the desired compound mixed with its regioisomer. A second chromatography using 1-3% isopropylamine in chloroform provided 5.21 g of the desired compound which solidified upon standing.
O 2-MethYi_ r~o~ane-thioamide.
A suspension of 100 g (1.15 mol) of isobutyramide in 4 L of diethyl ether was stirred vigorously and treated in portions with 51 g (0.115 mol) of P4S~o.
The resulting mixture was stirred at ambient temperature for 2 h, filtered, and concentrated in vacuo to provide 94.2 g (80%) of the crude desired compound.
1 H NMR (DMSO-dg) 81.08 (d, J = 7 Hz, 6 H), 2.78 (heptet, J = 7 Hz, 1 H), 9.06 (br, 1 H), 9.30 (br, 1 H). Mass spectrum: (M + H)+ = 104.
P 4-(Chloromethy~-2-isoorogvlthiazole hydrochloride A mixture of 94.0 g (0.91 mol) of 2-methylpropane-thioamide, 115.7 g (0.91 mol) of 1,3-dichloroacetone, and 109.7 g (0.91 mol) of MgS04 in 1.6 liters of acetone was heated at reflux for 3.5 h. The resulting mixture was allowed to cool, filtered, and the solvent was removed in vacuo to provide the crude desired compound as a yellow oil. 1 H NMR (DMSO-dg) 8 1.32 (d, J = 7 Hz, 6 H), 3.27 (heptet, J = 7 Hz, 1 H), 4.78 (s, 2 H), 7.61 (s, 1 H). Mass spectrum:
(M +
H)+ = 176.
Q 2-Iso~r vl-4-,~jN-methyl)aminolmethvl)thiazole.
A solution of 40 g of 4-(chloromethyl)-2-isopropylthiazole hydrochloride in 100 ml of water was added dropwise with stirring to 400 ml of 40% aqueous WO 95!20384 ~ ~ ~ g 6 3 2 PCT/US95100232 methylamine. The resulting solution was stirred for 1 h, then concentrated in vacuo. The residue was taken up in chloroform, dried over Na2S04, and concentrated in vacuo. Purification of the residue by silica gel chromatography using 10% methanol in chloroform provided 21.35 g (55%) of the desired compound. ~ H NMR (DMSO-ds) 8 1.34 (d, J = 7 Hz, 6 H), 2.56 (s, 3 H), 3.30 (heptet, J = 7 Hz, 1 H), 4.16 (s, 2 H), 7.63 (s, 1 H). Mass spectrum: (M + H)+
171.
R.R. N-(~l4-Nitro,~he,p,yl)oxy)c~rbonvl)-L-valine Met~l Ester.
A solution of 66.1 g (0.328 mol) of 4-nitrophenyl chloroformate in 1.2 liters of CH2C12 was cooled to OpC and treated with L-valine methyl ester hydrochloride. The resulting mixture was treated slowly, with stirring, with 68.9 ml (0.626 mol) of 4-methylmorpholine. The resulting solution was allowed to slowly warm to ambient temperature and was stirred overnight. After washing with 3 portions of 10% aqueous NaHC03, the solution was dried over Na2S04 and concentrated in vacuo. The residue was purified by silica gel chromatography by eluting with chloroform to provide the desired compound.
~ H NMR (DMSO-d6) 8 0.94 (d, J = 7 Hz, 3 H), 0.95 (d, J = 7 Hz, 3 H), 2.12 (octet, J = 7 Hz, 1 H), 3.69 (s, 3 H), 4.01 (dd, J = 8, 6 Hz, 1 H), 7.41 (dt, J = 9, 3 Hz, 2 H), 8.27 (dt, J = 9, 3 Hz, 2 H), 8.53 (d, J = 8 Hz, 1 H). Mass spectrum: (M +
NH4)+ _ 314.
N- N-M h I-N- 1-4- i r I - -v !in M~~yl Ester.
A solution of 15.7 g (92 mmol) of 2-isopropyl-4-(((N-methyl)amino)-methyl)thiazole in 200 ml of THF was combined with a solution of 20.5 g (69 mmol) of N-(((4-nitrophenyl)oxy)carbonyl)-L-valine methyl ester. The resulting solution was treated with 1.6 g of 4-dimethylaminopyridine and 12.9 ml (92 mmol) of triethylamine, heated at reflux for 2 h, allowed to cool, and concentrated in vacuo. The residue was taken up in CH2C12, washed extensively with 5% aqueous K2C03, dried over Na2S04, and concentrated in WO 95/20384 217 8 6.3 2 PCT~S95/00232 vacuo. The resulting product mixture was purified by silica gel chromatography using chloroform as an eluent to provide 16.3 g (54%) of the desired compound. ~ H NMR (DMSO-dg) 8 0.88 (d, J = 7 Hz, 3 H), 0.92 (d, J = 7 Hz, 3 H), 1.32 (d, J = 7 Hz, 3 H), 2.05 (octet, J = 7 Hz, 1 H), 2.86 (s, 3 H), 3.25 (heptet, J = 7 Hz, 1 H), 3.61 (s, 3 H), 3.96 (dd, J = 8, 7 Hz, 1 H), 4.44 {AA', 2 H), 6.58 (d, J
= 8 Hz, 1 H), 7.24 (s, 1 H). Mass spectrum: (M + H)+ = 328.
T. N-~(N-Methyl-N- j2-isol r~o~,yl-4-thiazolyl methyl~aminolcarbonvll-L-valine.
A solution of 1.42 g (4.3 mmol) of the resultant compound of Example 20S in 17 ml of dioxane was treated with 17.3 ml of 0.50 M aqueous LiOH. The resulting solution was stirred at ambient temperature for 30 min, treated with 8.7 ml of 1 M HCI, and concentrated in vacuo. The residue was taken up in dichloromethane, washed with water, dried over Na2S04, and concentrated in vacuo to provide 1.1 g (81%) of the desired compound. Mass spectrum: (M +
H)+= 314.
U. j2S.3S.5S~N-(N-(jN-Methvl-Nli(2-isopropyl-4 thiazol~lmethyl~aminolcarbonylwalin~~amino -1-2-(~j5 thiazolyl)methox~rarbon~)amino11.6-di~yl-3-h d~vhexane.
A solution of 70 mg (0.223 mmol) of N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine, 79 mg (0.186 mmol) of (2S,3S,5S)-5-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane, 30 mg (0.223 mmol) of 1-hydroxybenzotriazole hydrate, and 51 mg (0.266 mmol) of N-ethyl-N'-dimethylaminopropyl carbodiimide in 2 ml of THF was stirred at ambient temperature for 16 h. The resulting solution was concentrated in vacuo, and the residue was purified by silica gel chromatography using 97:3 CH2C12:CH30H to provide 100 mg (74%) of the desired compound (Rf 0.4, 95:5 CH2C12:CH30H) as a solid, mp 61-63~C. Mass spectrum: (M + H)+ = 721. Anal. Calcd for C37H4gNg0$52~0.5H20: C, 60.88;
H, 6.77; N, 11.51. Found: C, 60.68; H, 6.53; N, 11.36.

WO 95/20384 PCTlUS95100232 _29_ j2S.3S.5S~-2~jvJiN-dibenzyfamino)-3-hydroxy-5-(,t-buty~oxycarbonXjaminy-1-6 Jl~Xlhexane.
To a stirred solution of (2S,3S,5S)-2-(N,N-dibenzylamino)-3-hydroxy-5-amino-1,6-diphenylhexane (10.0 g, 21.6 mmol) in tetrahydrofuran (200 mL) was added potasium carbonate (6.0 g, 43.2 mmol) in H20 (200 mL). To this solution was added di-t-butyldicarbonate (5.64 g, 25.9 mmol) in tetrahydrofuran (10 mL).
The solution which resulted was stirred at room temperature for 3 hours. N,N-dimethylethylenediamine (1 mL, 8.6 mmol) was added and the reaction mixture was stirred at room temperature for an additional hour. Ethyl acetate (400 mL) was added and the organic layer was separated and washed with 5% KH2P04 (2 x 200 mL), water (1 x 200 mL), saturated NaHC03 (2 x 200 mL) and water (1 x 200 mL). The organic solution was then dried over sodium sulfate and concentrated under reduced pressure to provide the desired product as a light yellow oil. 300 MHz 1 H NMR (CDC13) 8 1.40 (s,9H), 1.58 (s, 2H), 2.45-2.85 (m, 4H), 3.05 (m, 1 H), 3.38 (d, 2H), 3.6 (m, 1 H), 3.79 (m, 1 H), 3.87 (d, 2H), 4.35 (s, 1 H), 4.85 (s, broad, 1 H), 7.0-7.38 (m, 20 H).
Fxaml I~ a 21 B
j2S.3S.5S)-2-amino-3-h~rdroxy-5-(t-butyloxycarbonylamin~-1.6 i~i~phenylhexane.
To a stirred solution of (2S,3S,5S)-2-(N,N-dibenzylamino)-3-hydroxy-5-(t-butyfoxycarbonylamino)-1,6-diphenylhexane (12 g, 21.3 mmol) in methanol (350 mL) was charged ammonium formate (8.05 g, i 28 mmol, 6.0 eq) and 10% palladium on carbon (2.4 g). The solution was stirred under nitrogen at 60 °C for three hours and then at 75 °C for 12 hours. An additional amount of ammonium formate (6 g) and 10% palladium on carbon (1.5 g) was added as well as 1 mL of glacial acetic acid. The reaction was driven to completion within 2 hours at a reflux temperature. The reaction mixture was then cooled to room temperature and then filtered through a bed ofCelite.*The filter cake was * Trade-mark washed with methanol (75 mL) and the combined filtrates were concentrated under reduced pressure. The residue was taken up in 1 N NaOH (300 mL) and extracted into methylene chloride (2 X 200 mL). The combined organic layers were washed with brine (250 mL) and dried over sodium sulfate.
Concentration of the solution under reduced pressure provided the desired product as a light colored oil which slowly crystallized upon standing (5 g).
Further purification of the product could be accomplished by flash chromatography (silica gel, 5% methanol in methylene chloride). 300 MHz 1 H
NMR (CDC13) b 1.42 (s, 9H), 1.58 (m, 1 H), 1.70 (m, 1 H), 2.20 (s, broad, 2H), 2.52 (m, 1 H), 2.76-2.95 (m, 4H), 3.50 (m, 1 H), 3.95 (m, 1 H), 4.80 (d, broad, 1 H), 7.15-7.30 (m, 10H).
Examlhe 2222 Alternative Pre~oaration ofl2S 3S 5S)-2-Amino-3-hydroxv-5-(t ~,yloxycarbonylamino)-1 6-diphenylhexane.
~xamnle 22A
;~)-2-!t Butvloxvcarbonylaminol-5-LN.N-dibenzvlaminol-1.6-diphenvl-4-oxo-2-hexene To 9.21 gm (20 mmol) of (S)-2-amino-5-(N,N-dibenzylamino)-1,6-diphenyl-4-oxo-2-hexene and 0.37 gm (3 mmol) 4-N,N-dimethylaminopyridine in 100 ml of methyl tert-butylether was added via syringe pump a solution containing 4.80 gm (22 mmol) di-tert-butyl Bicarbonate in the same solvent (25 ml) over a period of 6 h. An additional amount (3 ml) of methyl tert-butylether was then added to complete the addition. After stirring at room temperature for 18 h the reaction mixture was cooled with the aid of an ice water bath. The resultant solid was collected by suction filtration and washed with cold (0°C) methyl tert butylether and hexane and dried under vacuum to give 9.9 gm of crude material as a white solid. The material thus isolated was disolved in a minimal amount of dichloromethane and purified by flash chromatography on silica gel. Elution of the column with a mixture of hexane-ethyl acetate-~~?8632 ..,~. WO 95120384 PCTlUS95/00232 dichloromethane (8:1:1 ) gave, after concentration of the appropriate fractions, 8.1 gm (72%) of the desired compound. Mp. 191- 193°C. [a]p -183.7° (c =
1.05, CHC13). 1H NMR (CDCI~, $): 11.68 (bs, 1 H), 7.05 - 7.47 (m, 20H), 5.28 (s,1 H), 4.27 (d, J=16 Hz, 1 H), 4.02 (d, J=l6Hz, 1 H), 3.58 (m, 4H). 3.40 (m, 1 H), 3.11 (m, 1 H), 2.90 (m, 1 H), 1.48 (s, 9H).
aml I~ a 228 Alternate ~g;i~aratir~r~ of ~,~,~;,)-~t-Butyloxycarbonvtamino)-5-(N.N-_dj,~,~nzylamj~,~,-~,i6-di~,~,p"vl-4-o~~,o-2-hexene A suspension of (S)-2-amino-5-(N,N-dibenzylamino)-1,6-diphenyl-4-oxo-2-hexene (100.0 g, 0.217 mol) in 15% ethyl acetate/hexanes (2 liters) under N2 was warmed to about 40°C. The resulting solution was cooled to room temperature before adding 4.0 g (33 mmol) of N,N-dimethyl-4-aminopyridine and 49.7 g (0.228 mol) of di-tert-butyl dicarbonate. The reaction mixture was allowed to stir overnight at room temperature. (After approximately one hour, a white precipitate began to form.) The suspension was filtered and the precipitate was washed with hexanes to afford the desired product as colorless crystals. TLC: 25% ethyl acetate/hexanes Rf 0.38.
A solution of the product of Example 22A (5 g, 8.9mmol) in dichloromethane (1 OOmI) and 1,4-dioxolane (100m1) was cooled to between -10° and -15° C and treated dropwise with 1 M BH3THF (26.7m1, 26.7mmol).
The solution was stirred at this temperature for 3 hr. The clear solution was quenched with excess methanol (20m1) and stirred at room temperature for 30 min. The solvent was removed in vacuo.

WO 95/20384 ~ ~ ~ PCT/US95100232 The resulting white foam was dissolved in THF (75m1) and cooled to -40° C. A solution of LAH (9m1, 1 M in THF, 9mmol) was added dropwise.
After min. the solution was quenched with water followed by dilute aqueous HCI.
The organics were removed and the aqueous layer extracted with ethyl acetate (3 x 20 ml). The combined organics were washed (saturated aqueous bicarbonate followed by brine), dried (Na2S04), filtered and evaporated to afford 4.9 g (99%) of the desired product as a white foam.
Alternatively, the white foam resulting from the BH3THF reaction step was dissolved in MeOH (45m1), cooled to +3 °C and treated portionwise with KBH4 (1.44 g, 26.7 mmol). After addition of the last portion of KBH4 the reaction was stirred for an additional 4 hours at +4 to +5 °C. The solution was concentrated by 1 /2 the volume in vacuo, diluted with 1/1 hexane-EtOAc (70 ml) and quenched (with cooling, maintain temp. <30 °C) by adding a 10 %
solution of KHS04 to pH = about 5. NaOH (15 % aqueous) was added to pH = 12 - 13.
The insoluble salts were removed by filtration, and the filter cake washed 3 times with 7 ml 1/1 hexane/EtOAc. The filtrate and washes were transferred to a separatory funnel, diluted with 15 ml hexane and 15 ml H20. The organics were removed and the aqueous layer was extracted once with 20 ml (1 /1 ) hexane-EtOAc. The combined organics were washed (saturated brine), dried (Na2S04), filtered, and evaporated to afford 5.2 g of the desired product which was used without further purification in subsequent reactions.
Rf 0.5 (25% EtOAc/hexane) 1 H NMR (CDC13) b 7.37-7.10 (m 20H); 6.78 (br. s, 1 H); 4.62 (d, 1 H); 4.50 (s, 1 H); 4.18 (dd, 1 H); 3.9 (d, 2H); 3.65 (dd, 2H); 3.40 (d, 2H); 3.00 (m, 2H); 2.77 (m, 1 H); 1.39 (s, 9H). MS (El) m/e565 (M+H).
~xamole 22D
5S1-2-Amino-3-~yrdrox~5-(t-butyloxycarbonvlaminol-1.6-di~e~ylhexane.
A solution of the product from Example 22C (150 gm, 250 mmol) dissolved in absolute EtOH (2 liters) was treated with 10 % Pd/C (l8gm, pre-wetted), followed by addition of ammonium formate (78.6 gms, 1.25 moles) dissolved in H20 (200m1). The resulting mixture was stirred at reflux for 2.5 ,,~., WO 95/20384 ~ ~ PCT/US95/00232 hours. The mixture was cooled to room temperature and filtered through a pad of infusorial earth (20g). The filter cake was washed 3 times with EtOH (70m1 each). The filtrate was concentrated in vacuo. The residue was dissolved into EtOAc (1 L) and washed (1 N NaOH, followed by H20, followed by brine), dried (Na2S04), filtered and concentrated in vacuo. to a constant weight of 95 gms.
(99.2 % of theory). The light yellow solid (91.5 gm of the 95 gm) was slurried in hot heptane (600 ml) (steam bath) and treated with isopropanol (45m1), and swirled to effect solution. The solution was allowed to slowly cool to room temperature over 3 hours, kept at room temperature for 2 more hours and filtered. The filter cake was washed 10 times with 9/1 hexane-isopropanol (30m1 each) to give the desired product as an off-white finely crystalline solid which was dried to constant weight of 57.5 gm.
The crude product (20 gm) was recrystallized from hot 140 ml heptane/
17 ml isopropanol. After letting the solution cool slowly to room temperature, the mixture was let stand at room temperature for 2 hours and then filtered.
The filter cake was rinsed (5 X 15 ml (8/1 ) heptane/isopropanol) and dried to a constant weight of 18.5 gm.

thiazoly,~j;~g~t~,Y[lyrnin~,lcal onyl)vaiinvllamino -2-l~,N-(,(5=
hiazoly~, me~r~xy~~,~,yl~,amino)-1.6-Biphenyl-3-hydroxvhexane ~?~.,;~ .S~L~ (t-Butvloxycarbonylamino)-2-lN-ll5 I~l~lYllm.~th.~~1t.~h'~!n~il~)-1.6-d i ~o he nyrl-3-hyd roxyhexan a The product of Example 22D (6.0g , 15.6 mmoles) was dissolved in 60 mL of DMF under nitrogen atmosphere. To this stirred solution at room temperature was added 5-(p-nitrophenyloxycarbonyloxymethyl)thiazole (4.67g , 15.6 mmole) and the resulting solution was stirred for 4 h. The solvent was removed under reduced pressure by rotary evaporation and the residue dissolved in 150 mL EtOAc. This solution was washed with 5 x 75 mL 1 N
NaOH solution, 100 mL brine, dried over Na2S04. The solvent was removed WO 95/20384 217 $ 6 3 2 PCTNS95100232 to afford 8.02 g of a slightly yellowish oil. This material was crystallized from 30 mL EtOAc and 40 mL hexane to afford 6.53g (80%) of the desired product as a white solid. mp 118-120 ~C H ~NMR (CDC13) 8 8.79 (s, 1 H), 7.83 (s, 1 H), 7.30-7.15 (m, 8H), 7.08 (m, 2H), 5.23 (s, 2H), 5.14 (d, 1 H, J = 9 Hz), 4.52 (m, 1 H), 3.92-3.72 (m, 3H), 3.65 (m, 1 H), 2.85 (d-apparent, 2H, J = 7.5 Hz), 2.72 (d-apparent, 2H, J = 7 Hz), 1.61 (m, 2H), 1.38 (s, 9H). CIMS m/z (526) (M + H)+, 543 (M + 18)+~.
nvllaminol-1 The product of Example 23A (6.43g, 12.23 mmoles) was dissolved in 25 mL dioxane at room temperature under nitrogen atmosphere. To this stirred solution was added 20.25 mL of 4N HCI in dioxane, and after approximately 10 min a thick precipitate formed. An additional 10 mL of dioxane was added to loosen up the slurry. This mixture was stirred for 1 h and then filtered. The filter cake of the product bis-HCI salt was washed with 20 mL dioxane, air dried, and then dissolved in 175 mL water. To this solution was added 175 mL ethyl acetate and the two phase mixture rapidly stirred. The pH of this mixture was adjusted to pH = 10 by the dropwise addition of 3N NaOH to the rapidly stirred mixture. The organic layer was isolated, washed with brine (150 mL), and dried over Na2S04. The solvent was removed to afford 5.18g (99%) of the desired product as a clear oil. H1 NMR (CDC13) 8 8.B1 (s, 1 H), 7.87 (s, 1 H), 7.35-7.05 (m, 10 H), 5.33 (d, 1 H, J = 9.3 Hz), 5.28 (m,2H), 3.81 (m, 1 H), 3.72 (m, 1 H), 3.01 (m, 1 H), 2.88 (m, 2H), 2.78 (dd, 1 H, J = 13.5, 5.1 Hz), 2.39 (dd, 1 H, J =
9.0, 4.5 Hz), 1.57-1.30 (m, 2H). CIMS m/z 426 (M + H)+.
ExamDI
~2S.3S.5Sa-~N-~N-((N-Methyl-N- (2-iso~~y thiazolv~jmethyl)amino)carbonyl)valinyllamino~~-,~N-(!5 thiazol~lmethoxxcarbon~,yllamino)~-1.6-Biphenyl-3-hydroxyhexane N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L
valine (4.13g, 13.18 mmole) and hydroxybenztriazole (2.23g, 16.48 mmoles) were dissolved in 70 mL THF and then dicyclohexyl-carbodiimide( 2.71 g, 13.18 WO 95/20384 ~ PCT/US95100232 mmoles) was added in one portion to the stirred solution under nitrogen atmosphere. This mixture was stirred for 4h at room temperature and then filtered to remove dicyclohexylurea precipitate. (2S,3S,5S)-5-Amino-2-(N-((5-thiazolyl)-methoxycarbonyl)amino)-1,6-Biphenyl-3-hydroxyhexane (5.1 g, 11.99 mmoles) was dissolved in 100 mL THF under nitrogen atmosphere. To this stirred solution was added the filtrate of HOST-active ester and the resulting solution was stirred at room temperature for 4 h, and the solvent removed via rotary evaporation. The residue was dissolved in 150 mL ethyl acetate and washed with 2 x 100 mL 1 N NaOH, 100 mL brine, 100 mL of 1 % w/w aqueous KHS04 and the solvent was removed by rotary evaporation to afford a residue.
The residue was dissolved in 175 mL 1 N HCL, and the solution filtered to remove the small quantity of dicyclohexylurea. The filtrate solution was added to 175 mL ethyl acetate and the two phase mixture rapidly mixed. The pH of this rapidly stirred mixture was adjusted to pH = 7 by dropwise addition of cold 3N NaOH. The organic layer was isolated, washed with 100 mL brine, dried over Na2S04, filtered, and the solvent was removed to afford 8.6 g of a colorless foam. This material was crystallized from 42 mL EtOAc and 21 mL
hexane to give 7.85g of the desired product as a white solid. mp = 122-123 ~C.
CIMS m/z 721 (M + H) +.
The product of Example 17F (9.~ g, 33.4 mmol) and phenylboronic acid (4.1 g, 33.6 mmol) were combined in toluene (150 mL) and refluxed for 2.5 hours with azeotropic water removal (Dean-Stark trap). Toluene (100 mL) was distilled out at atmospheric pressure, then the remaining toluene was removed under vacuum, to provide a yellow syrup which was dissolved in DMF (50 mL) and cooled to -60 °C. A solution of 5-(p-nitrophenyloxycarbonyloxy-methyl)thiazole (9.5 g, 33.5 mmol) in DMF (50 mL) was added over 45 minutes.
The resulting mixture was stirred for 8 hours at -5515 °C, then 14 hours at WO 95/20384 217 8 6 3 2 PCT~S95100232 -25°C, then was allowed to warm to room temperature. The reaction mixture was diluted with 1 N HCI (250 mL) and washed with CH2C12 (2 x 80 mL). The combined organic layers were back-extracted with 1 N HCI (60 mL). The combined aqueous HCI layers were cooled in an ice-bath to 2 °C, and conc.
(37%) HCL (30 mL) was added over 5 minutes. The desired product (bis HCI
salt) began to precipitate within 30 minutes. The slurry was stirred 3 hours at 2-°C, then the product (bis HCI salt) was collected by filtration and dried in a vacuum oven at 55-60 °C. Yield 11.4 g (68%).
Second crop recovery:
The HCI mother liquors were stirred with ethyl acetate (190 mL) and neutralized to pH 9-10 with aqueous K2C03 (200-300 g of 25% w/w K2C03 was required). The ethyl acetate layer was concentrated under vacuum to an oil which was redissolved in 1 N HCI (90 mL) and washed with methylene chloride (45 mL). The aqueous layer was cooled to 2 °C. Conc. (37%) HCI
(9.0 mL) was added to precipitate a second crop. After stirring for 1-3 hours at 2-°C, the solid was collected by filtration and dried in a vacuum oven at 55-60 °C.
Yield 2.1 g (12.6%).
Neutralization of Bis HCI Salt:
The bis HCI salt (10.66 g, 21.4 mmol, mixture of first and second crops) was stirred with CH2C12 (110 mL) and 5% aqueous NaHCOg (110 mL) until all solids dissolved (2 hours). The aqueous layer was separated and extracted with another 50 mL CH2C12. The combined organic extracts were dried with Na2S04 (10 g), filtered and concentrated under vacuum at <_40 °C to an oil.
The oil was dried on a vacuum pump to give the title compound as a yellow foam, 9.1 g (100 %).
Alternative B
The product of Example 17F (15.0 g, 0.053 mole) was dissolved in DMF
(75 mL). Triisopropylborate (24.4 mL, 0.105 mole) was added and stirred at ambient temperature for approximately 1.5 hours. The solution was cooled to ...... WO 95/20384 PCT/US95100232 ?78632 -10°C and a solution of 5-(p-nitorphenyloxycarbonyloxymethyl)thiazole (15.0 g, 0.054 mole) in DMF (75 mL) was added over 80 minutes. The reaction was stirred for approximately 1 hour at -10 °C, then was diluted with methylene chloride (250 mL) and quenched with a mixture of triethanolamine (24.8 g) and 5% aqueous sodium bicarbonate (300 mL). The biphasic mixture was stirred for 1 hour, then the layers were separated and the aqueous was extracted with another portion of methylene chloride (50 mL). The combined organic layers were extracted with 1 N HCI (1 x 390 mL, then 1 x 95 mL). The acid layers were combined, cooled in an ice-bath, and further acidified with conc. HCI (50 mL) which produced a white slurry of product. The slurry was stirred for approximately 1 hour at 2°C. The desired product bis HCI salt) was collected by filtration and dried at 55 °C in a vacuum oven. Yield '18.5 g (70%).
~DIa 25 hia oly~,lme hvll~~~Z~r~~r onvl)valinyl)aminol-2-(N-((5-thiazojyllm~?thoxvcarbQayrl)amino-1.6-di~henyl-3-hydroxyhexane To a solution of the product of Example 24 (9.1 g, 21.4 mmol), HOBT (3.6 g, 23.5 mmol) and N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)-L-valine (7.37 g, 23.5 mmol) in THF (170 mL) was added DCC (4.85 g, 23.5 mmol). The solution was stirred at ambient temperature for 16 hours (DCU precipitates). THF was removed under vacuum and the resulting paste was stirred with cold 1 N HCI (106 mL at 5 °C) for 3 hours to dissolve the the crude product. The DCU was removed by filtration and the filter cake was washed with 1 N HCI (30 mL). KH2P04 (3.2 g) was dissolved in the combined HCI filtrates. The solution was mixed with ethyl acetate (80 mL) and neutralized to pH 7 with aqueous NaOH (60.3 g of 10% w/w NaOH). The aqueous layer was extracted with another 25 mL ethyl acetate and the combined ethyl acetate extracts were washed with aqueous NaHC03 (2 x 37 mL of 5% w/w NaHC03).
The organic layer was dried with Na2S04 (13 g), filtered, and concentrated under vacuum at <_45 °C. The residue was dissolved in a 1:1 ethyl acetate/heptane mixture (200 mL) at 70 °C. The solution was allowed to cool slowly and stirred overnight at room temperature to provide a thick slurry.
The product was collected by filtration and washed with 1:1 ethyl acetate/heptane WO 95120384 ~,~ ~ ~ PCT/US95/00232 (20 mL). The product was dried briefly at 55 °C in a vacuum oven to obtain an approximate weight prior to the second crystallization (12.85 g, 83%).
A second crystallization from 144 mL of 2:1 ethyl acetate/heptane (dissolved at ~70 °C, then stirred at room temperature 12 hours) produced a thick slurry of fine white solid. The product was collected by filtration and washed with 15 mL
2:1 ethyl acetate/heptane, then dried in a vacuum oven at 55 °C for 2 days to give the desired product. Yield 11.9 g (77%).
Example 26 Alternate Preparation of (j5-Thiazolyl)methyl)-(,4-nitroohenyllcarbonate 2-Amino-5-(ethoxycarbonyl~thiazoie Hydrochloride To a -10 °C solution of potassium tert-butoxide (110 g, 0.98 mol) in THF
(1.9 L) was added a solution of ethyl chloroacetate (100 mL, 0.934 mol) and ethyl formate (75 mL, 0.928 mol) in THF (400 mL) dropwise over 2 hours, with good mechanical stirring. The thick solution was stirred another 2 hours at ca.
-1 °C then the reaction was quenched by addition of a solution of NaCI
(150 g) in 1 N HCL (750 mL). The mixture was allowed to warm to 20 °C and the lower aqueous layer (containing some precipitated salt) was separated. The organic layer was stripped under vacuum on a rotary evaporator. The oil was redissolved in 500 mL ethyl acetate. dried with 75 g Na2S04 for 1 hour, filtered and concentrated under vacuum (40-50 °C bath temperature) to an oil.
The resulting crude chloroaldehyde (161 g) and thiourea (70 g, 0.92 mol) were dissolved in THF (2 L) and warmed to gentle reflux (60 °C). The thiourea dissolved during warming, and within 20 minutes, product precipitated from solution. After 100 minutes the suspension was allowed to cool to room temperature, then was cooled in an ice-bath for 1 hour. The product was collected on a fritted Buchner funnel and washed with 2 x 100 mL cold THF, then dried overnight in a vacuum oven at 50 °C. Yield: 122 g of title compound as a tan-colored solid, m.p. 182-185 °C (dec.). 1 H NMR (DMSO-dg) 8 7.86 (s, 1 H), 4.19 (q, 2H), 1.21 (t, 3H). ~3C NMR (DMSO-dg) 8 171.9, 160.4, 140.4, 114.4, 61.1, 14.2.

"._ WO 95/20384 ~ ~ 7 8 6 3 2 pCT~S95/00232 ExamQj, 26B
2-Amino-5~(,e~ oxycarbonvllthiazole To a -10 °C solution of potassium tent-butoxide (150 g, 1.3 mol) in THF
(1.35 L) was added a solution of ethyl chloroacetate (139 mL, 1.3 mol) and ethyl formate (103 mL, 1.27 mol) in THF (150 mL) dropwise. over 75 minutes, with good mechanical stirring. A THF rinse (25 mL) was added over 5 minutes. The thick solution was stirred another 3 hours at ca. -5 to 0 °C, then the reaction was quenched by addition of a solution of NaCI (240 g) and conc. HCI (90 mL) in water (960 mL). The mixture was allowed to warm to 15 °C and the lower aqueous layer was discarded. Thiaurea (97 g, 1.27 mol) was dissolved in the crude THF solution of chloroaldehyde. The solution was warmed to 65 °C
and refluxed for 1 hour, then cooled to 30 °C. Addition of a solution of K2C03 (88g, 0.64 mol) in 1500 mL water produced two layers (aqueous pH=7). The THF
was removed under vacuum at <_45 °C, causing the product to precipitate as a yellow solid. The slurry was cooled to 15 °C, and the product was collected on a fritted Buchner funnel and washed with 3 x 200 mL water, then dried 24 hours in a vacuum oven at 55 °C to provide 151 g of title compound as a yellow solid, m.p. 155-158 °C. 1 H NMR (DMSO-ds) 8 7.8 (br s, 2H, NH2), 7.62 (s, 1 H), 4.13 (q, 2H), 1.18 (t, 3H). t3C NMR (DMSO-dg) ~ 173.4, 161.3, 147.9, 114.5, 60.1, 14.3.
5-(Ft xvr r~b~nyjlthiazole A solution of 2-amino-5-(ethoxycarbonyl)thiaZOle (50 g, 0.29 mmol) in a mixture of DMF (83 mL) and THF (317 mL) was added dropwise over 87 minutes to a stirred 41 °C solution of isoamyl nitrite (59 mL, 0.44 mol) in DMF
(130 mL). A maximum temperature of 60 °C was observed during the exothermic addition. After another 40 minutes the THF was removed under vacuum at 45 °C. The concentrated DMF solution was cooled to 25 °C and diluted with toluene (420 mL) and water (440 mL). The toluene layer was extracted with 3 x 120 mL water, then dried with Na~S04 (50 g) for 1 hour.
After filtration the toluene layer was stripped on a rotary evaporater at 50 °C bath temperature, then on a vacuum pump at 21 °C. The crude residue containing WO 95/20384 2 ~ 7 8 b 3 2 PCT~S95/00232 the title compound weighed 65.6 g. This material was used directly in the next step. A sample of similarly prepared material was purified by column chromatography to give a yellow oil. ~ H NMR (CDC13) ~ 8.95 (s, 1 H), 8.51 (s, 1 H), 4.39 (q, 2H), 1.40 (t, 3H). ~3C NMR (CDC13) b 161.0, 157.9, 148.6, 129.8, 61.6, 14.1.
Examol ~ltjvdroxymethyl thiazole To a slurry of lithium aluminum hydride (9.0 g) in THF (633 mL) was added a solution of crude 5-(ethoxycarbonyl)thiazole (65.6 g) in THF (540 mL) over 95 minutes at 0-5 °C. After an additional 25 minutes, the reaction was quenched at 5 °C by sequential addition of water (8.1 mL), 15% NaOH
(8.1 mL), and water (24.3 mL). After drying with Na2S04 (44 g) for 2 hours, the slurry was filtered, and the filter cake was washed with 100 mL THF. The combined filtrates were concentrated under vacuum at 45 °C to a brown oil (39 g). The oil was fractionally distilled through a short-path apparatus. The product fractions distilled at 97-104 °C vapor temperature at 3-5 mm, providing 20.5 g of the title compound as a turbid orange oil. ~ H NMR (CDC13) 8 8.74 (s, 1 H), 7.72 (s, 1 H), 4.89 (s, 2H), 3.4 (br s, 1 H, OH). ~3C NMR (CDC13) 8 153.4, 140.0, 139.5, 56.6.
,~;'ole 26E
~(u-~ Nitrol~yoxy~,rarbonyj~,~,y~r~y1)thiazole Hydrochloride Distilled 5-(hydroxymethyl)thiazole (14.1 g, 123 mmol) and triethylamine (17.9 mL, 129 mmol) were dissolved in ethyl acetate (141 mL) and cooled to -1 °C (ice/salt bath). A solution of 4-nitrophenyl chloroformate (26.0 g, 129 mmol) dissolved in ethyl acetate (106 mL) was added dropwise over 50 minutes at an internal temperature of 0-4 °C. An ethyl acetate flask rinse (20 mL) was also added. Salts precipitated from solution throughout the addition.
The yellow mixture was stirred another 1 hour 45 minutes at 0-2 °C, then a solution of dilute HCI (3.1 g, 31 mmol of conc. NCI in 103 mL water) was added at once. The mixture was stirred for 0.5 hours while warming to 15 °C, then stirring was stopped. The organic layer was washed twice with aqueous 5%
K2C03 solution (2 x 70 mL), then dried with Na2S04 (30 g). After filtration the WO 95120384 ~ ~ ~ PCT/US95/00232 solution was concentrated under vacuum on a rotary evaporator (bath temperature of 41 °C) to a brown oil (38g). The crude 5-(p-nitrophenyoxycarbonyloxymethyl)-thiazole was dissolved in ethyl acetate (282 mL), then cooled in an ice bath to 2 °C. Dry HCI gas (7.1 g, 195 mmol) was bubbled in slowly over 50 minutes (temperature 2-4 °C). After stirring for another 1 hour 45 minutes at 2-4°C, the solid precipitate was collected on a sintered glass funnel under a nitrogen blanket and the flask was washed out with 50 mL cold ethyl acetate which was used to rinse the filter cake. The cake was dried on the funnel under strong nitrogen purge for 15 minutes then dried in a vacuum oven at 50 °C with a nitrogen purge to provide 29.05 g of the title compound as tan powder, m.p. 131-135 °C (dec.). 1 H NMR (DMSO-dg) 8 9.21 (d, 1 H), 8.27 (m, 2H), 8.06 (d, 1 H), 7.52 (m, 2H), 5.54 (s, 2H). 13C NMR
(DMSO-dg) 8 157.3, 155.2, 151.8, 145.3, 143.7, 131.9, 125.5, 122.7, fi2.1.
Exam Ip a 2fiF
5-( -p Nitroa~noxycarbonyloxy et ~~~)thiazole 5-(p-Nitrophenoxycarbonyloxymethyl)thiazole hydrochloride (3.0 g) was slurried in ethyl acetate (30 mL) and cooled to 10-15 °C. A
solution of 5% aqueous potassium carbonate (30 mL) was added with rapid stirring. After 15 minutes, stirring was stopped and the aqueous layer was separated. The organic layer was dried with Na2S04 (3 g), filtered, and solvent was distilled under vacuum to give 2.49 g of the title compound as a brown syrup which slowly solidified, m.p. 62-64 °C. 1 H NMR (CDC13) b 8.90 (d, 1 H), 8.29 (m, 2H), 8.01 (d, 1 H), 7.39 (m, 2H), 5.52 (s, 2H). ~3C NMR (CDC13) 155.4, 155.2, 152.2, 145.4, 144.9, 130.6, 125.3, 121.6, 61.9.

WO 95/20384 21 l 8 6 3 2 pCT~S95/00232 Example 27 Alternative Preparation of N-(-(N-Methyl-N- ~2-isoaroovl-4 thiazolvl)methyl)aminolcarbon~,)-L-valine Exam Ip a 27A
Thioisobutvramide To a 1 liter three neck round bottom flask equipped with mechanical stirrer, nitrogen atmosphere, condensor, thermocouple and 15 ° C water bath was charged (26.0 g, 0.298 mots) isobutyramide followed by ( 19.9 g, 0.045 mots) phosphorous pentasulfide and 375 mls THF. This solution was stirred at 20 ~ 5 ° C for 3 hours, then was warmed to 60 °C and stirred an additional 3 hours. The THF was removed under vacuum with a 50 ° C bath temperature to afford a yellow oil. This oil was neutralized with a solution of 5 g NaOH, 10 g NaCI and 90 g water. Next the product was extracted into EtOAc (2 X 250 mls) and the combined organics reduced under vacuum to an oil. The oil was dissolved in 50 mls THF and again the solvent was removed under vacuum to give the desired product as a yellow oil. (yield approx. 27 grams, 88%).
Examiple 27B
2-Iso,~ro~, I-4- ,~~N-methyl)amino)methvl)thiazole The thioisobutyramide resulting from Example 24A was dissolved in 70 mls THF and added slowly to a solution of (34.1 g , .27 mots) 1,3-dichloracetone in 40 mls THF. A 10 ml rinse of THF was used to completely transfer the thioamide. The reaction wass carried out in a 250 ml flask with mechanical stirring under nitrogen atmosphere. The reaction temperature was maintained below 25 ° C during addition with a 15 ~ 5 ° C bath. The bath was kept in place for 1 hour after which it was removed and the reaction stirred for 18 hours.
Next this stirred chloromethyl-thiazole solution was added to 376 mls (4.37 mots) 40 % aqueous methylamine solution at 15 ° C in a 1 liter flask. The temperature was maintained below 25 ° C during addition. After half an hour the bath was removed and the reaction stirred for 3 hours at ambient temperature. The solvent was removed under vacuum with a 50 ° C bath to an end volume of mls. The residue was then basified with 50 g 10 % NaOH to pH 12 and .._, WO 95/20384 ~ ~ ~ PCTlUS95100232 extracted into methylene chloride {2 X 160 mls). The combined organics were then washed with 1 X 150 g of 20 % ammonium chloride followed by 1 X 90 g of 20 % ammonium chloride. The combined aqueous washes were then back extracted with 150 mls methylene chloride. The combined product methylene chloride layers were then extracted with 100 g of a solution of 25 g conc. HCI
and 75 g water. This acidic product solution was then washed with 135 mls methylene chloride. Next the acidic product solution was cooled, then neutralized with 100 g 20 % NaOH solution. The product was extracted from this mixture with methylene chloride (2 X 135 mls). The solvent was removed under vacuum to afford the desired product as an amber oil. (yield approx. 28 grams) Methvl Ester Into a 500 ml 3-neck round bottom flask equipped with mechanical stirrer, nitrogen atmosphere, thermocouple, heating mantle and condensor was charged the product of Example 27B (28.1 g, .165 mols), phenoxycarbonyl-(L)-valine (41.5 g, .165 mol} and 155 ml toluene. This solution was warmed to reflux (110 °C) and stirred for three hours, then cooled to 20~
5° C and washed with 2 X 69 ml 10 % citric acid followed by 1 X 69 ml water, 1 X 116 mls 4 sodium hydroxide, 1 X 58 ml 4 % sodium hydroxide and finally 1 X 58 ml water.
The organic product solution was then treated with 3 grams of activated carbon at reflux for 15 minutes , filtered through infusorial earth to remove carbon, and the carbon/infusorial earth cake was washed with 25 ml hot toluene. Next the solvent was removed to afford a brown oil which solidifed upon cooling. This brown solid was dissolved with warming in 31 ml EtOAc and 257 ml heptane at 60~5° C. This solution was slowly cooled to 25 °C, stirred 12 hours, cooled further to 0°C, and stirred 3 hours. The crystals were collected by filtration and washed with 50 ml 1:9 EtOAc/Heptane. The solid was dried in a 50°C
vacuum oven for 12 hours to afford 41.5 grams of the desired product as a tan-colored solid (76.9%).

WO 95/20384 PC"T/US95/00232 ~G(N-d~gth~~,j2-isoi~roRyt-4-thiazolyl)methyl)aminolcarbonyll-L-valine To a one liter three neck flask was charged the product of Example 27C
(50 g, 0.153 mol), lithium hydroxide monohydrate (i 3 g, 0.310 mol), 200 ml THF
and 190 ml water. This hazy solution was stirred for 2 hours. The reaction was quenched with a solution of conc. NCI (32.4 g, 0.329 mol) in 65 mL water, the THF was removed under vacuum and the product extracted into methylene chloride (3 X 210 ml). (NOTE: If necessary, the pH of the aqueous layer should be adjusted to maintain pH 1-4 during the extractions.) The combined organics were then dried with 50 g sodium sulfate, filtered with a 150 ml methylene chloride rinse of the sodium sulfate, and the solvent was removed under vacuum. The product was dissolved in 450 ml THF and again the solvent was removed. Next the product was dissolved in 475 ml THF containing 0.12 g butylated hydroxytoluene (BHT) for storage. If desired, the solvent can be removed under vacuum and the residual syrup dried in a vacuum oven at 55 °C
to provide a glassy solid.
The above process for the preparation of compound III is disclosed in PCT Patent Application No. W094114436, published July 7, 1994.
Protocol For Oral Bioavailabilityr Studies Protocol A solid dosage formsl Dogs (beagle dogs; mixed sexes, weighing 7-14 kg) were fasted overnight prior to dosing, but were permitted water adad libitum. Each dog received a 0.5 mg/kg subcutaneous dose of histamine approximately 30 minutes prior to dosing. Each dog received a single solid dosage form corresponding to a 5 mglkg dose of the drug. The dose was followed by approximately 10 milliliters of water. Blood samples were obtained from each ~. WO 95/20384 ~ ~ ~ PCT/US95/00232 animal prior to dosing at 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug administration. The plasma was separated from the red cells by centrifugation and frozen (-30°C) until analysis. Concentrations of parent drug were determined by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The parent drug area under the curve was calculated by the trapezoidal method over the time course of the study. The absolute bioavailability of each test composition was calculated by comparing the area under the curve after oral dosing to that obtained from a single intravenous dose. Each capsule or capsule composition was evaluated in a group containing six dogs; the values reported are averages for each group of dogs. The average bioavailability data for the compositions of the Examples is shown in Table I.
Dogs (beagle dogs, mixed sexes, weighing 7-14 kg) were fasted overnight prior to dosing, but were permitted water ad libit~,. Each dog received a 0.5 mg/kg subcutaneous dose of histamine approximately 30 minutes prior to dosing. A 5 mg/kg dose, measured in a disposable syringe, was placed in the back of the throat of each animal. The dose was followed by approximately 10 milliliters of water. Blood samples were obtained from each animal prior to dosing at 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug administration. The plasma was separated from the red cells by centrifugation and frozen (-30°C) until analysis. Concentrations of parent drug were determined by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The parent drug area under the curve was calculated by the trapezoidal method over the time course of the study. The absolute bioavailability of each test composition was calculated by comparing the area under the curve after oral dosing to that obtained from a single intravenous dose. Each liquid composition was evaluated in a group containing six dogs; the values reported are averages for each group of dogs. The average bioavailability data for the compositions of the Examples is shown in Table I.

217 8 6 3 2 PCTlUS95/00232 Protocol C lliauid dos ~e form. followed by milkl The animals were selected and pretreated with histamine as described in Protocol B above. The liquid dosage form (5 mg/kg dose), measured in a plastic syringe, was instilled into the back of the throat of each animal. A
10 mL
aliquot of milk was also administered into the back of the throat of each dog.
The liquid dosage form/milk combination was chased with an additional aliquot of water as described in Protocol B above. The sampling times, sample preparation and data analysis were as described in Protocol B.
Protocol D l~j"r~uid dosage form with milkl The animals were selected and pretreated with histamine as described in Protocol B above. The liquid dosage form (5 mg/kg dose) was diluted ten fold with milk. The diluted dosage was measured in a plastic syringe and instilled into the back of the throat of each animal. The liquid dosage form was chased with an additional aliquot of water as described in Protocol B above.
The sampling times, sample preparation and data analysis were as described in Protocol B.

..-.. WO 95120384 . ~ ~ PCT/US95/00232 Mean E~amo_, 1e /, Bjga" vailalbilitvProton, No.

Example 1 0.0 A

Example 2 0.0 A

Example 3 2.5 A

Example 4 37.4 B

Example 5 56.7 D

Example 6 72.7 B

Example 7 42.1 C

Example 8 62.0 D

Example 9 53.7 D

Example 10 78.9 C

Example 11 100.0 C

Example 12 58.3 B

Example 13 89.7 C

Example 14 65.1 C

Example 16 87.2 C

Example 17 78.2 C

Example 18 66.4 C

Example 19 100.0 C

This data indicates that solution formulations provided significantly better bioavailability than non-formulated compound III.
Compounds I, II and III are inhibitors of HIV-1 and HIV-2 protease. They are useful for inhibiting an HIV infection and treating AIDS in humans. Total daily dose of compound I, II or III administered to a human in single or divided doses may be in amounts, for example, from 0.001 to 1000 mg/kg body weight daily but more usually 0.1 to 50 mg/kg body weight daily. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drugs administered in combination and the severity of the particular disease undergoing therapy.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds, methods and compositions.
Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

Claims (24)

CLAIMS:
1. A pharmaceutical composition comprising a solution of a compound of the formula:
in a pharmaceutically acceptable organic solvent comprising a mixture of:
(1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoreate, polyethylene glycol sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof; and (2) ethanol or propylene glycol;
provided that when solvent (1) is propylene glycol, then solvent (2) is ethanol.
2. The composition of Claim 1 comprising a solution of the compound of the formula:
in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol or polyoxyethyleneglycerol triricinoleate or a mixture thereof; and (2) ethanol.
3. The composition of Claim 1, further comprising a pharmaceutically acceptable acid or a mixture of pharmaceutically acceptable acids.
4. The composition of Claim 2, further comprising a pharmaceutically acceptable acid or a mixture of pharmaceutically acceptable acids.
5. The composition of Claim 1 wherein said compound is (2S, 3S, 5S)-5-(N-(N-((NMethyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane.
6. The composition of Claim 1, further comprising citric acid.
7. The composition of Claim 5, further comprising citric acid.
8. The composition of any one of Claims 1 to 6 further comprising water.
9. The composition of Claim 7 further comprising water.
10. The composition of any one of Claims 1 to 9 further comprising one or more additives independently selected from pharmaceutically acceptable organic solvents, pharmaceutically acceptable oils, pharmaceutically acceptable sweetening agents, pharmaceutically acceptable flavoring agents, pharmaceutically acceptable surfactants and antioxidants.
11. The composition of Claim 1 comprising a solution of from about 1% to about 15% by weight of the total solution of the compound of the formula:
in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 10% to about 50% by weight of the total solution or polyoxyethyleneglyceral triricinoleate in the amount of from about 5% to about 35% by weight of the total solution or a mixture thereof and (2) ethanol in the amount of from about 5% to about 45% by weight of the total solution.
12. The composition of Claim 11 further comprising a pharmaceutically acceptable acid in the amount of from about 0.2% to about 16% by weight of total solution.
13. The composition of Claim 11 comprising a solution of from about 1% to about 15% by weight of the total solution of (2S, 3S, 5S)-5-(N-(N-((NMethyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N((5thiazolyl)methoxycarbonyl)amino~)-1,6-diphenyl-3-hydroxyhexane in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 10% to about 50% by weight of the total solution or polyoxyethyleneglycerol triricinoleate in the amount of from about 5% to about 35% by weight of the total solution or a mixture thereof and (2) ethanol in the amount of from about 5% to about 45% by weight of the total solution.
14. The composition of Claim 13 further comprising a pharmaceutically acceptable acid in the amount of from about 0.2% to about 16% by weight of total solution.
15. The composition of Claim 14 wherein the pharmaceutically acceptable acid is citric acid.
16. The composition of Claim 9 comprising a solution of about 5% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and about 4% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of about 42% by weight of the total solution, (2) ethanol in the amount of about 32% by weight of the total solution and (3) water in the amount of about 17%
by weight of the total solution.
17. The composition of Claim 9 comprising a solution of about 12% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and from about 3% to about 4% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of about 32% by weight of the total solution, (2)ethanol in the amount of about 32% by weight of the total solution and (3) water in the amount of about 15% by weight of the total solution.
18. The composition of Claim 7 comprising a solution of about 5% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and from about 5% to about 6% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 44% to about 45% by weight of the total solution, (2) ethanol in the amount of about 24% by weight of the total solution and (3) polyoxyethyleneglycerol triricinoleate in the amount of about 20% by weight of the total solution.
19. The composition of Claim 7 comprising a solution of about 10% by weight of the total solution of (2S,3S,55)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and from about 5% to about 6% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 39% to about 40% by weight of the total solution, (2) ethanol in the amount of about 24% by weight of the total solution and (3) polyoxyethyleneglycerol triricinoleate in the amount of about 20% by weight of the total solution.
20. The composition of Claim 9 comprising a solution of from about 2%to about 3% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N((2-isopropyl 4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N
((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and about 4% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of about 43% by weight of the total solution, (2) ethanol in the amount of about 33% by weight of the total solution and (3) water in the amount of about 17%
by weight of the total solution.
21. The composition of Claim 9 comprising a solution of about 5% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and from about 0.3 to about 0.4% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of about 36% by weight of the total solution, (2) ethanol in the amount of about 36% by weight of the total solution and (3) water in the amount of about 19% by weight of the total solution.
22. The composition of Claim 9 comprising a solution of about 8% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-l,6-diphenyl-3-hydroxyhexane and from about 0.3 to about 0.4% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of about 35% by weight of the total solution, (2)ethanol in the amount of about 35% by weight of the total solution and (3) water in the amount of about 18% by weight of the total solution.
23. The composition of Claim 8 comprising a solution of from about 7% to about 8% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((N-Methyl-N((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)mino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and about 0.5% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 45% to about 46% by weight of the total solution, (2) ethanol in the amount of about 21% by weight of the total solution and (3) polyoxyethyleneglycerol triricinoleate in the amount of from about 24% to about 25% by weight of the total solution.
24. A pharmaceutical composition comprising a solution of from about 7% to about 8% by weight of the total solution of (2S,3S,5S)-5-(N-(N-((NMethyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane and from about 0.2% to about 0.3% by weight of the total solution of citric acid in a pharmaceutically acceptable organic solvent comprising a mixture of (1) propylene glycol in the amount of from about 31 % to about 32% by weight of the total solution, (2) ethanol in the amount of about 32% by weight of the total solution, (3) polyoxyethyleneglycerol triricinoleate in the amount of from about 10% to about 11% by weight of the total solution; and (4) water in an amount of from about 14% to about 15% by weight of the total solution.
CA002178632A 1994-01-28 1995-01-03 Pharmaceutical compositions containing hiv protease inhibitors Expired - Lifetime CA2178632C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002540258A CA2540258A1 (en) 1994-01-28 1995-01-03 Pharmaceutical compositions containing hiv protease inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18902194A 1994-01-28 1994-01-28
US08/189,021 1994-01-28
US28323994A 1994-07-29 1994-07-29
US08/283,239 1994-07-29
PCT/US1995/000232 WO1995020384A1 (en) 1994-01-28 1995-01-03 Pharmaceutical compositions containing hiv protease inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002540258A Division CA2540258A1 (en) 1994-01-28 1995-01-03 Pharmaceutical compositions containing hiv protease inhibitors

Publications (2)

Publication Number Publication Date
CA2178632A1 CA2178632A1 (en) 1995-08-03
CA2178632C true CA2178632C (en) 2006-04-11

Family

ID=26884695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002178632A Expired - Lifetime CA2178632C (en) 1994-01-28 1995-01-03 Pharmaceutical compositions containing hiv protease inhibitors

Country Status (13)

Country Link
US (1) US5484801A (en)
EP (1) EP0732923B1 (en)
JP (1) JP4353542B2 (en)
KR (1) KR100360963B1 (en)
AT (1) ATE210441T1 (en)
AU (1) AU700942B2 (en)
CA (1) CA2178632C (en)
DE (1) DE69524567T2 (en)
DK (1) DK0732923T3 (en)
ES (1) ES2169121T3 (en)
IL (1) IL111991A (en)
PT (1) PT732923E (en)
WO (1) WO1995020384A1 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014436A1 (en) * 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
EP0769936A1 (en) * 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
US5705524A (en) * 1994-11-04 1998-01-06 Gilead Sciences, Inc. Thiepane compounds
US6034118A (en) * 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ES2246498T3 (en) 1995-11-13 2006-02-16 Vitaleech Bioscience N.V. ISOLATED ANTIVIRALS OBTAINED FROM SANGUIJUELAS.
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
AU3146997A (en) * 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
ID21649A (en) 1996-10-18 1999-07-08 Vertex Pharma INHIBITOR SERUM PROTEASE, ESPECIALLY VIRUS HEPATITIS C NS3 PROTEASE
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
CO5090830A1 (en) 1998-07-20 2001-10-30 Abbott Lab POLIFORM OF A PHARMACEUTICAL AGENT
US6894171B1 (en) * 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CA2351516A1 (en) * 1998-11-18 2000-05-25 Valery Alakhov Copolymer compositions for treating viral infections
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
BE1012622A3 (en) * 1999-04-21 2001-01-09 Solvay PROCESS TO SEPARATE AND REACTIVE ENANTIOMERS enantiopure.
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
SK286305B6 (en) * 1999-06-04 2008-07-07 Abbott Laboratoires Improved pharmaceutical formulations comprising ritonavir
AU6109500A (en) * 1999-07-20 2001-02-05 Merck & Co., Inc. Alpha-hydroxy-gamma-(((carbocyclic-or heterocyclic-substituted)amino)carbonyl)alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
ATE329579T1 (en) 1999-11-12 2006-07-15 Abbott Lab SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP2003514910A (en) 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Gamma-hydroxy-2- (fluoroalkylaminocarbonyl) -1-piperazinepentanamides as HIV protease inhibitors
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CZ304118B6 (en) 2000-01-19 2013-11-06 Abbott Laboratories Pharmaceutical composition
US7138538B2 (en) * 2000-04-14 2006-11-21 Solvay (Societe Anonyme) Process for the separation of enantiomers and enantiopure reagent
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
WO2002020057A2 (en) * 2000-09-05 2002-03-14 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
US6555558B2 (en) * 2000-10-31 2003-04-29 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage self-emulsifying formulations of pyranone protease inhibitors
WO2002051414A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2002078669A1 (en) * 2001-03-30 2002-10-10 Takeda Chemical Industries, Ltd. Medicinal solutions
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
CN1649614A (en) 2002-02-22 2005-08-03 新河药品股份有限公司 Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
UA81003C2 (en) * 2002-12-16 2007-11-26 Boehringer Ingelheim Int Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ545871A (en) * 2003-09-12 2010-04-30 Vertex Pharma Animal model for protease activity and liver damage
CA2541634A1 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
CN1894276B (en) * 2003-10-27 2010-06-16 威特克斯医药股份有限公司 HCV NS3-NS4A protease resistance mutants
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20130083938A (en) * 2004-10-01 2013-07-23 버텍스 파마슈티칼스 인코포레이티드 Hcv ns3-ns4a protease inhibition
TWI437990B (en) 2004-10-29 2014-05-21 Vertex Pharma Medical use of vx-950
WO2006090270A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Acid addition salt of 2-isopropyl-4-(((n-methyl)amino)methyl)thiazole and its?use in the preparation of ritonavir
BRPI0614696A2 (en) * 2005-07-29 2011-04-12 Tibotec Pharm Ltd macrocyclic hepatitis c virus inhibitors
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
MY141245A (en) * 2005-07-29 2010-03-31 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Macrocylic Inhibitors Hepatitis C Virus
RU2441870C2 (en) * 2005-07-29 2012-02-10 Тиботек Фармасьютикалз Лтд. Macrocyclic inhibitors of hepatitis c virus
WO2007014925A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
PE20070210A1 (en) 2005-07-29 2007-04-16 Tibotec Pharm Ltd MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
EP1919898B1 (en) * 2005-07-29 2011-01-26 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
CA2617679A1 (en) 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
KR20080072906A (en) 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Hepatitis C Virus Variants
WO2007098270A2 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
AU2007227544B2 (en) * 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
DK2097402T3 (en) 2006-11-17 2014-06-30 Janssen R & D Ireland MACROCYCLIC INHIBITORS OF HEPATITIS C-VIRUS
WO2008095999A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Pyrimidine substituted macrocyclic hcv inhibitors
MX2009009176A (en) * 2007-02-27 2009-09-28 Vertex Pharma Inhibitors of serine proteases.
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
ATE530546T1 (en) * 2007-08-30 2011-11-15 Vertex Pharma COCRYSTALS AND PHARMACEUTICAL COMPOSITIONS THEREOF
CA2700132A1 (en) * 2007-09-25 2009-04-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
RU2508105C2 (en) * 2007-10-29 2014-02-27 Сипла Лимитед New antiretroviral combination
PA8809601A1 (en) * 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
UY31950A (en) * 2008-07-01 2010-01-29 Medivir Ab CYCLOPROPIL-POLYMERASE INHIBITORS
JP2012517478A (en) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド HCV combination therapy comprising pegylated interferon, ribavirin and telaprevir
MA33212B1 (en) 2009-04-25 2012-04-02 Hoffmann La Roche METHODS FOR IMPROVING PHARMACOKINETICS
AU2010254415B2 (en) 2009-05-27 2013-07-04 Merck Sharp & Dohme Corp. HIV protease inhibitors
TW201130502A (en) 2010-01-29 2011-09-16 Vertex Pharma Therapies for treating hepatitis C virus infection
WO2012010942A2 (en) 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation Amorphous ritonavir co-precipitated
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
CN104755475B (en) 2012-09-11 2016-12-28 默沙东公司 Hiv protease inhibitor
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
UA117375C2 (en) 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
WO2015056213A1 (en) 2013-10-17 2015-04-23 Medivir Ab Hcv polymerase inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3083609B1 (en) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3116862B1 (en) 2014-03-10 2019-04-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086165A (en) * 1989-03-08 1992-02-04 Washington University Inhibitors of retroviral protease with a ketomethylene isosteric replaced amide bond
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5256677A (en) * 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5164300A (en) * 1989-12-28 1992-11-17 Washington University Method for determining activity of retroviral protease
AU8233491A (en) * 1990-07-06 1992-02-04 Smithkline Beecham Corporation Retroviral protease inhibitors
US5171662A (en) * 1990-09-13 1992-12-15 The Upjohn Company Method of detecting HIV protease activity
US5183826A (en) * 1990-09-25 1993-02-02 Merck & Co., Inc. Antiviral agent
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
JPH06505495A (en) * 1991-03-08 1994-06-23 スミスクライン・ビーチャム・コーポレイション HIV protease inhibitor
EP0532466A3 (en) * 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
US5250563A (en) * 1991-09-25 1993-10-05 Merck & Co., Inc. Inhibitors of HIV protease
US5296604A (en) * 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
WO1994014436A1 (en) * 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
ATE210441T1 (en) 2001-12-15
HK1011609A1 (en) 1999-07-16
CA2178632A1 (en) 1995-08-03
IL111991A0 (en) 1995-03-15
DK0732923T3 (en) 2002-04-08
PT732923E (en) 2002-05-31
US5484801A (en) 1996-01-16
IL111991A (en) 2000-07-26
JP4353542B2 (en) 2009-10-28
KR100360963B1 (en) 2003-02-11
DE69524567T2 (en) 2002-09-05
ES2169121T3 (en) 2002-07-01
AU1524895A (en) 1995-08-15
EP0732923B1 (en) 2001-12-12
DE69524567D1 (en) 2002-01-24
EP0732923A1 (en) 1996-09-25
AU700942B2 (en) 1999-01-14
WO1995020384A1 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
CA2178632C (en) Pharmaceutical compositions containing hiv protease inhibitors
US5610193A (en) Pharmaceutical composition
AU695516B2 (en) Pharmaceutical composition of HIV-protease inhibitors
EP1183026B1 (en) Improved pharmaceutical formulations comprising ritonavir
CA2540258A1 (en) Pharmaceutical compositions containing hiv protease inhibitors
HK1011609B (en) Pharmaceutical compositions containing hiv protease inhibitors
MXPA96002984A (en) Pharmaceutical compositions containing protease inhibitors
HK1045804B (en) Improved pharmaceutical formulations comprising ritonavir
HK1151471A (en) Improved pharmaceutical formulations

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150105